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ABSTRACT 
Regulation and Function of the Rho GTPase Mediated Signaling Pathways in Metastasis 
and Lenticular Differentiation. (May 2006) 
Dianne Courtenay Mitchell, B.S., Oklahoma State University 
Chair of Advisory Committee:  Dr. Mingyao Liu 
 
Modulation of the actin-based cytoskeleton and transcription factor regulation are 
merely two essential functions in a wide array of cellular activities that the Rho family of 
small GTPases is responsible for mediating.  Aberrations in, or loss of, Rho GTPase 
signaling has been found to lead to multiple pathologies, including both metastatic 
progression and lenticular differentiation leading to cataractogenesis.  This study has 
examined the   transcriptional regulation of the metastasis suppressor, KiSS-1.  Although 
the mechanism by which KiSS-1 modulates an anti-metastatic effect is not entirely known, 
it is known that KiSS-1 mediates stress fiber formation, increased adhesion and reduced 
migratory and invasive properties through modulation of the Rho family of small GTPases.  
The loss of KiSS-1 that commonly occurs during metastatic progression, leads to a loss of 
proper Rho GTPase regulation.  This study has examined how KiSS-1 is regulated in two 
tissue types, breast and skin, and how the loss of AP-2α and DRIP-130, respectively, leads 
to the progression of breast cancer and melanoma.  In addition, this study has also looked 
at the importance of Rac1 expression and function in the lens epithelium.  Activation of 
Rac1 and its downstream effector, SRF, have been shown to be key regulators in lens cell 
differentiation, possibly leading to lens opacification via its transcriptional control of the 
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structural crystallins within the lens.  The results of this dissertation research have made 
significant strides in understanding the nature of the anti-metastatic effects registered by 
the novel KiSS-1 peptide and its cognate GPCR.  Additionally, it has shed light on the Rho 
family regulation of lens epithelial cell differentiation, indicating the elaborate 
involvement of Rac1 in mediating lens fiber development.  In all, this research has 
determined previously unknown roles of small molecule GTPases in both the progression 
of metastasis, as well as in normal and abnormal lens cell differentiation. 
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CHAPTER I 
INTRODUCTION TO METASTASIS SUPPRESSOR KISS-1 
 
Maintaining tight regulation of cellular activities including differentiation, 
proliferation and migration is essential in preserving a normal cell phenotype. This control 
is mediated through the association of extracellular molecules, including various growth 
factors, with their receptors in order to modify the intracellular signal transduction 
pathways that affect cellular changes. Normal cells exhibit a highly dynamic nature; 
regulation is maintained by switching from one pathway to the next as exposure to 
different environmental stimuli varies. Mutations of genes encoding cell cycle regulators or 
proto-oncogene such as ras, Src, and epidermal growth factor receptor or to tumor 
suppressor genes, tip the balance and induce transformation to an immortalized, 
unregulated cancer cell phenotype. Cancers most commonly result from the compounding 
of multiple genetic mutations that lead to aberrations in essential cell function (Bieche and 
Lidereau, 1995). 
The vast majority of breast cancer deaths occurring each year result from 
complications caused by tumor cell metastasis, rather than as a consequence of the original 
tumor.  Once tumorigenic cells enter into the vascular and lymphatic  systems,  they  travel  
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peripheral regions where they invade tissues and form neoplasms.  Metastasis is a process 
requiring detachment of cancer cells from the primary site, survival of sheer forces 
encountered in the circulation, migration to other organs, attachment to and invasion of 
tissues, proliferation of these cells at the secondary site, and finally the capacity to enlist 
neighboring capillaries to supply the tumor with nutrients as it develops.  Thus, migration, 
invasion and angiogenesis are as crucial to tumor formation and metastasis as they are to 
normal cell growth and proliferation.  Interference at any one of these steps can block this 
metastatic cascade thereby preventing the formation of metastatic growths.  Consequently, 
there is an increasing interest in studying the metastatic process in order to identify 
possible ways to inhibit its progression.  Our laboratory, and other groups have determined 
that the KiSS-1 peptide inhibits cell migration and invasion, thus interfering with the 
metastatic cascade and preventing tumor metastasis.   
Research has also shown that the expression of the KiSS-1 peptide, like many other 
tumor suppressor genes, is reduced or absent in breast cancer metastases.  Unlike tumor 
suppressor genes, metastasis suppressors like KiSS-1 function by inhibiting metastasis of 
cancer cells to secondary sites, therefore abrogating the spread of cancer.  Most metastasis 
inhibitors have only been identified over the past 5-10 years, and the mechanisms through 
which they modulate their anti-metastatic effects have not yet been determined.  It is 
known, however, that the effects of KiSS-1 are mediated through its cell surface receptor 
protein, the KiSS-1 receptor which transduces the presence of the peptide into downstream 
signaling events.  Experiments have shown that overexpression and activation of the KiSS-
1 receptor by its ligand in highly metastatic breast cancer cells permits cells to recover 
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their metastatic inhibition.  Similar to that of other metastasis suppressors, the inverse 
correlation of KiSS-1 receptor activation with a higher incidence of breast cancer 
metastasis is clear, although the mechanism of this association remains obscure (Shevde 
and Welch, 2003; Steeg et al., 2003).  Our laboratory has begun to characterize the 
mechanism by which the KiSS-1 receptor elicits its anti-metastatic effect, principally 
through close examination of its downstream signaling pathways and through 
understanding of the mechanisms controlling its transcription. This research will help to 
determine the overall effects modulated by the activated KiSS-1 receptor and to identify 
which signaling pathways are important for conveying the anti-metastatic effect of 
activated KiSS-1 receptor in breast cancer cells.  By gaining a better understanding of the 
metastatic cascade and the role activated KiSS-1 receptor plays in preventing breast cancer 
metastases, this research may lead to new methods of breast cancer intervention and 
provide new means of breast cancer prevention.   
G-protein coupled receptors (GPCRs) are integral membrane proteins that bind 
specific external ligands.  Upon ligand binding, GPCRs transduce signals across the 
membrane via activation of heterotrimeric GTP-binding proteins, which initiate an 
intracellular cascade of signaling events. GPCRs are composed of seven transmembrane 
regions, and upon activation, either the intracellular loops or carboxy-tail mediate G-
protein interaction. The heterotrimeric G-protein complex consists of α, β and γ subunits 
which modulate distinct internal signaling pathways (Gudermann et al., 1997). G-proteins 
are intrinsic to JNK, MAPK and PLC-β signaling pathways, indicating they play an 
important role in cytoskeletal reorganization, migration, and invasion (Gutkind, 1998). 
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Subsequently, overexpression of some GPCRs has been directly linked to the onset of 
cancers (Dhanasekaran et al., 1995; Zohn et al., 2000).  
Like other GPCRs, the KiSS-1 receptor transduces the presence of an external 
stimulant to the interior of the cell, thus initiating a series of internal signaling cascades 
that mediate the effects of that stimulant.  In the case of the KiSS-1 receptor, the stimulant 
is the KiSS-1 peptide, and the signaling events induced by of this peptide lead to the 
suppression of breast cancer metastasis.  The KiSS-1 peptide has been recognized as a 
potent metastasis suppressor in previous studies (Lee et al., 1996; Lee and Welch, 1997a).  
Its anti-metastatic properties were identified through subtractive hybridization analysis 
during which microcell-mediated replacement of KiSS-1 expression in C8161 melanoma 
cells suppressed melanoma metastasis by 95% as compared to untreated melanoma (Lee et 
al., 1996). 
Breast cancer cells commonly show a loss of various chromosomal regions 
resulting in loss of heterozygosity.  The region on which the KiSS-1 peptide resides 
(chromosome 1q) is one of these chromosomal regions that are frequently lost during 
breast cancer development.  Reintroduction of KiSS-1 expression in human breast 
carcinoma cell lines (MDA-MB-435) results in the dramatic suppression of metastasis (Lee 
and Welch, 1997a).  Similar in vivo studies showed that injection of metastatic cells over-
expressing KiSS-1 peptide into the mammary fat pads of athymic nude mice resulted in 
decreased metastasis of the breast cancer to the lung or lymph nodes (Lee and Welch, 
1997b). 
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It is the activation of the KiSS-1 receptor that conveys the presence of the peptide 
and initiates those signaling events that eventuate metastatic inhibition of breast cancer.  
Upon activation of the receptor by its ligand, the KiSS-1 receptor increases internal 
calcium levels in Chinese hamster ovary cells, suggesting a strong signaling response 
within the cell (Ohtaki et al., 2001).  Likewise, activated KiSS-1 receptor mediates the 
excessive formation of focal adhesions and stress fibers, indicating increased adhesion and 
decreased migratory and invasiveness of these cells (Ohtaki et al., 2001).  This data 
suggests that activation of KiSS-1 receptor may induce an excessively adhesive phenotype 
which results in a loss of cell motility.   
 Although the correlation between increased activation of KiSS-1 receptor and 
increased metastatic inhibition in cancer cells is clear, the mechanism through which 
activated KiSS-1 receptor prohibits breast cancer metastasis remains unknown.  Our 
laboratory has recently cloned the human and mouse isoforms of KiSS-1 receptor, as well 
as its ligand (Stafford et al., 2002). The mouse forms of KiSS-1 receptor and peptide show 
a high degree of homology, indicating that they have been well conserved over the course 
of evolution in order to serve a necessary molecular function. In our preliminary 
experiments, we have shown that activation of KiSS-1 receptor by its ligand can inhibit 
cell proliferation, migration, and invasion in NIH3T3 cells (Stafford et al., 2002).   
Because the metastatic cascade is composed of many separate and distinct 
processes (migration, adhesion, invasion, etc.), many signaling pathways are involved in 
its overall regulation.  GTPases, proteins that regulate G-protein coupling and membrane 
receptor activity, are commonly involved in tumorigenesis and have been shown to elicit a 
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substantial effect on cancer metastasis (Figure 1). Suppression of either Cdc42 or Rac 
leads to decreased cell spreading and decreased tumor metastasis.  Migration, invasion, and 
vascularization require clustering of basement membrane-associated integrins and the 
recruitment of cytoskeletal adaptor proteins such as focal adhesion kinase (FAK). Integrins 
are transmembrane glycoproteins that interact with extracellular matrix proteins to induce 
mitogenic, chemotaxic and adhesive functions within the cell (Rolli et al., 2003).   FAK 
influences migration, proliferation and cell survival changes and activates Rac and JNK 
(Hsia et al., 2003) promoting tumor cell metastasis. Vascular endothelial growth factor 
(VEGF) induces the proto-oncogene Src to associate with FAK to promote cell invasion, 
angiogenesis and migration (Hsia et al., 2003).  Our laboratory has recently shown that 
active FAK is downregulated upon overexpression of activated KiSS-1 receptor, 
suggesting a possible mechanism by which KiSS-1 receptor modulates its anti-metastatic 
properties (Stafford et al., unpublished data). 
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Figure 1:  Possible KiSS-1 Mediated Signaling Pathways 
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CHAPTER II 
MATERIALS AND METHODS 
 
Cell Culture and Cell Transfection 
MCF-7, MDA-231, MDA-435, and T47D cells were obtained from the American 
Type Culture Collection (Manassas, VA).   Dulbecco’s modified Eagle’s medium and 
RPMI 1640 with phenol red, 100X antibiotics, and fetal bovine serum were purchased from 
HyClone (Logan, UT).  Media for melanoma lines (A375SM, MeWo, SB2, and WM2664) 
was supplemented with Hepes Buffer (Hyclone; Logan, UT) and 100X MEM Non-
Essential Amino Acids (Gibco; Grand Island, NY).  Transfection of both breast and 
melanoma cell lines was carried out according to the manufacturer’s protocol (Invitrogen).  
In brief, DNA was added using a Lipofectamine to DNA ratio of 2:1 to each well of a 6- or 
24-well plate or 100-mm dish for a period of 6 hours. Empty vector was used to offset the 
difference in DNA concentrations in reactions in which fewer test plasmids were 
transfected. Transfection reagent was then removed from each well, and cells were 
incubated in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine 
serum for 24 hours before assaying. 
Chemicals, Constructs, and Oligonucleotides  
[γ-32P]ATP (300 Ci/mmol) was obtained from PerkinElmer Life Sciences 
(Wellesley, MA). Poly(dI-dC) and T4 polynucleotide kinase were purchased from Roche 
Molecular Biochemicals (Indianapolis, IN).  Antibodies for Sp1, AP-2α, IgG, and actin 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Luciferase reagent and 
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lysis buffer were obtained from Promega Corp. (Madison, WI). The 1.2-kb KiSS-1 
promoter was cloned from BAC clone RP11–203F10 (accession AL592114) using primers 
consisting of XhoI and KpnI sites for ligation into the pGL3-basic vector from Promega 
Corp. (Madison, WI); sense, 5'-GGGGTACCAGACTGCCGGCATGCTT-3' and antisense, 
5'-CCGCTCGAGTT-CTCCCCAGCTCCCTGATCACATCC-3'. All other KiSS-1 
promoter mutants and truncated fragments were likewise cloned into XhoI and KpnI sites 
in the pGL3-basic vector. Expression vectors for AP-2α, AP-2B, and Sp1 were cloned as 
previously described (Tellez and Bar-Eli, 2003). The Sp1-∆DBDconstruct was cloned into 
pCDNA3.1 (Invitrogen) and was generated from the full-length Sp1 construct with PCR 
primers, which excluded the DNA-binding region; sense, 5'-CGGAATTCATGAGCG-
ACCAA-GATCACTCCATGGATC-3' and antisense, 5'-CCGCTCGAGGAAGCCA-
TTGC-CACTGATATTAAT-3'.  Additionally, antibodies for DRIP-130 were obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA). The DRIP-130 construct was provided 
by Dr. Jun Qin (Baylor, Houston, TX).   
Luciferase Assay 
Cells were cultured in 24-well plates in Dulbecco’s modified Eagle’s medium or 
RPMI 1640 supplemented with 10% fetal bovine serum. After 18–20 h when cells were 
∼60% confluent, reporter gene constructs were transfected using Lipofectamine reagent 
according to the manufacturer’s protocol (Invitrogen). In brief, 1 µg of total DNA was 
transfected into each well of a 24-well plate using a Lipofectamine to DNA ratio of 2:1 for 
a period of 6 hours. Empty vector was used to offset the difference in DNA concentrations 
in reactions in which fewer test plasmids were transfected. Transfection reagent was then 
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removed from each well, and cells were incubated in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum. Cells were harvested after 48 hours, and 
luciferase activity of protein lysates was measured following the manufacturer’s protocol 
(Luciferase Assay System, Promega).  To normalize for differences in cell line transfection 
efficiencies, all cells were transfected with pRSV-β-gal control vector (Promega).  β-
Galactosidase levels were then measured following the manufacturer’s protocol (Galacto-
Light Plus, Bedford, MA).  
Western Immunoblot Analysis 
Breast and melanoma cell lines (2.0 × 107) were seeded in 100-mm Petri dishes 
with 10 ml of complete medium and incubated overnight. The cells were then scraped off 
and washed in cold phosphate-buffered saline. The cell pellet was then lysed in 0.5 ml of 
RIPA buffer (1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 
M sodium phosphate, pH 7.2, 2 mM EDTA, 50 mM sodium fluoride, 0.2 mM sodium 
vanadate, 100 units/ml aprotinin). Soluble proteins were then separated by centrifugation at 
15,000 µg for 5 minutes at 4 °C. Protein concentration was determined. Samples were then 
diluted into loading buffer at 1 mg/ml. Following heat denaturation, samples containing 10 
µg of protein were loaded onto and separated on 10% or 15% SDS-PAGE gels as needed. 
Proteins were then transferred electrophoretically to 0.45-µm nitrocellulose membrane 
(Pall Corp., Pensacola, FL). After incubating the membranes in blocking solution, primary 
antibody was added at 1:1,000 dilution, followed by secondary antibody incubation at 
1:10,000. Proteins were detected using the  SuperSignal West Pico Chemiluminescent 
substrate (Pierce) according to the manufacturer’s instructions.   
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To extract total proteins from the cornea, retina, or the whole lens, different part of 
the mouse eye tissues were dissected out and grinded under liquid nitrogen to make a fine 
powder and suspended in cell lysis buffer (Li et al., 2001).  The insoluble material was 
subsequently removed by centrifugation.   For each sample, the protein concentration was 
determined as previously described (Li et al., 2001).   Western blot analysis of total 
proteins was conducted as described before (Li et al., 2003).   Briefly, 100 ng of total 
proteins in each sample were resolved by 15% SDS-polyacrylamide gel.  The protein blots 
were blocked with 5% milk in TBS (10 mM Tris·HCl, pH8.0/ 150 mM NaCl) overnight at 
4oC, and incubated with primary antibodies as described above.   Following incubation 
with the primary antibody, the membrane was exposed to a horseradish peroxidase 
conjugated secondary antibody, subjected to SuperSignal West Pico Chemiluminescent 
reagent (Pierce Biotechnology, Inc.), and exposed to film.  A single protected band at 
approximately 21 kDa was observed for each GTPase-specific antibody used.   
Electrophoretic Mobility Shift Assay (EMSA) 
For electrophoretic mobility shift assay (EMSA), nuclear extracts from MCF-7, 
A375SM and WM2664 cells were harvested as described previously (Abdelrahim et al., 
2004). Protein concentrations of nuclear extracts were determined using BCA assay 
(Pierce). Aliquots of nuclear protein were frozen and stored at -80 °C until used.  KiSS-1 
promoter-derived oligonucleotides were synthesized and annealed, and 5 pmol was 5'-
endlabeled using T4 Kinase and [γ32-P]ATP. A 30-µl EMSA reaction containing ∼100 
mM potassium chloride, 3 µg of crude nuclear extract, 1µg of poly(dI-dC) with or without 
unlabeled competitor oligonucleotide, and 10 fmol of labeled probe was incubated on ice 
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for 20 minutes. A Sp1-specific antibody was then incubated in appropriate reactions for 20 
min on ice. A separate AP-2 antibody was used for gel-shift analysis (Active Motif, 
Montreal, Canada). DNA-protein complexes were then resolved on 5% PAGE gel at ∼120 
V at room temperature for 2 hour.  Antibody-protein complexes were observed as 
supershifted or immuno-depleted complexes. 
Chromatin Immunoprecipitation (ChIP) Assay 
Chromatin immunoprecipitation (ChIP) was performed following the protocol 
outlined by the ChIP assay kit (Upstate Biotechnology, Lake Placid, NY). Briefly, MCF-7 
cells transfected with both AP-2α and Sp1 (2 × 107 cells) were fixed with 1% 
formaldehyde, scraped into conical tubes, pelleted, and lysed in SDS lysis buffer containing 
1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, and 1µg/ml pepstatin A. DNA 
was sheared to fragments of 200–500-bp by eight 10 second sonications. The chromatin 
was precleared with salmon sperm DNA/protein A-agarose slurry (Upstate Biotechnology) 
for 1 h at 4 °C with gentle agitation. The agarose beads were pelleted, and the precleared 
supernatant was incubated with antibodies to IgG, AP-2α, and Sp1 overnight at 4 °C. The 
region between +288 and +188 of the KiSS-1 promoter was amplified from the 
immunoprecipitated chromatin using the following primers: sense, 5'-
ATAGCCCATTTCCACGTTG-3' and antisense, 5'-GGCGGGACTTTCTCCTTC-3'. 
Following PCR, the 100-bp product was resolved on a 2.5% agarose gel and stained with 
ethidium bromide. Samples were visualized under UV light.  Additionally, chromatin 
immunoprecipitation (ChIP) was performed using A375SM and WM2664 cells transfected 
with both DRIP-130 and Sp1 as previously described (Mitchell et al., 2006).  The 
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precleared supernatant was incubated with antibodies to IgG, DRIP-130, and Sp1 overnight 
at 4 °C. The region between +1 and +156 of the KiSS-1 promoter was amplified from the 
immunoprecipitated chromatin using the following primers: sense, 5'-
TTCTCCCCAGCTCCCTGATCACATCC-3' and antisense, 5'-CTGCCTCCAGT-
CACAGAGC-3'.  Following PCR, the ∼150-bp product was resolved on a 2.5% agarose 
gel and stained with ethidium bromide. Samples were visualized under UV light. 
Co-Immunoprecipitation Analysis 
Interactions of AP-2α and Sp1 in transfected MCF-7 cells were examined by 
immunoprecipitation (IP) and by western blot analysis. Briefly, cells were lysed with RIPA 
buffer containing 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 10 mM Tris, 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 20 mM NaF, 10 mg/ml phenylmethylsulfonyl 
fluoride, 1 mg/ml aprotinin, and 1 mg/ml leupeptin, followed by sonication with a 550 
Sonic dismembrator (Fisher Scientific) and immunoprecipitated with the indicated 
antibodies. A anti-AP-2α and anti-Sp1 immunocomplexes were recovered by using protein 
A beads (Sigma). All immunoprecipitates were washed with lysis buffer (4X) and were 
separated by SDS-PAGE and then transferred to polyvinylidene difluoride membranes 
(Millipore). After incubation in TBST buffer (20 mM Tris-HCl, pH 7.5/500 mM 
NaCl/0.02% Tween 20) containing 0.2% bovine serum albumin and 5% dry milk powder 
for 2 hours, the membranes were probed with the indicated antibodies and visualized with 
the SuperSignal West Pico detection system (Pierce). 
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Semiquantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)  
Total RNA was isolated from breast cancer and melanoma cell lines with TRIzol 
reagent (Invitrogen).  First-strand cDNA synthesis was performed using Moloney murine 
leukemia virus reverse transcriptase and oligo(dT) (Promega) according to the 
manufacturer’s protocol. Primer sequences used for detection of KiSS-1 transcripts were 5'-
GCCCACCATGAACTCACTG-3' and 5'-CTGC-CCCGCACCTGCG-3'. Amplified 
products were ∼400 bases in length. Additionally, primers for β-actin were 5'-
GGCTCCGGCATGTGCAAGGC-3' and 5'-AGATTTTCTCCATGTCGTCC-3', which 
resulted in PCR products of ∼200 bases.  Optimal PCR cycles required for linear 
amplification for each set was determined.  β-Actin required 21–23 cycles per reaction, 
whereas KiSS-1 required 24–28 cycles. PCR products were separated using agarose gels of 
appropriate concentration, visualized by EtBr staining and quantitated using Alpha Imager 
software (Alpha Innotech, San Leandro, CA). 
Invasion and Migration Assays 
A375SM and WM2664 melanoma cell lines were transiently transfected with both 
DRIP-130 and Sp1 or with vector alone.  Transfection efficiency was determined visually 
upon transfection of a GFP-tagged vector.  As described earlier, cell migration assays were 
carried out in modified Boyden chambers (Banyard et al., 2000; Stafford et al., 2002).  
Briefly, the outside of the filters were coated with either 1 µg/ml collagen for 1 hour and 
then washed three times with PBS.  Filters were then incubated with DMEM with BSA for 
1 hour.  Filters were then put into DMEM medium without FBS and with 0.5 ng of mouse 
bFGF.  Both melanoma lines were seeded at approximately 20,000 cells/well on top of the 
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filter.  Plates were incubated 18 hours.  Excess cells that did not migrate through the filter 
were removed from the inside of the filter.  Cells were fixed with 4% paraformaldehyde for 
20 minutes, washed three times with PBS, and then stained with crystal violet.  Stained 
cells were examined and counted under the microscope.  Additionally, scratch assays were 
carried out on Sp1/DRIP-130 co-transfected A375SM and WM2664 cells.  Cells were 
allowed to grow to confluency on plates coated with collagen and washed twice with PBS. 
Cells were then scratched with a pipette tip and washed five more times with PBS. Fresh 
DMEM was added with 0.5 ng of mouse bFGF. This was allowed to incubate for 24 hours 
and pictures were taken using a Nikon digital camera. 
Animals 
 The C57BL/6 mice were used in all experiments.  Animals were maintained in a 12 
h light/dark cycles and fed normal diet and water.   Mice used in this study were handled in 
compliance with the “Guide for the Care and Use of Laboratory Animals” (National 
Academy Press) and also with the ARVO Statement for the Use of Animals in Ophthalmic 
and Vision Research. 
Preparation of Embryo Sections 
 Ocular tissues were fixed in Zinc-formalin fixative and processed by Excalibar 
Pathology (Moore, Oklahoma).  The slides were deparaffinized with xylene, rehydrated, 
bathed in 3% H2O2 at 37 °C to quench the endogenous peroxidase, and protein antigens 
were unmasked by steaming slides in citrate solution for 45 minutes.   
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Immunohistochemistry 
 Immunohistochemistry (IHC) of paraffin embedded tissues was performed using 
the ABC-Staining System according to manufacturer’s instructions (Santa Cruz 
Biotechnology).  All sections were counterstained with Harris Modified Hematoxylin with 
acetic acid (Fisher Scientific).  Polyclonal antibodies to RhoA, Rac1 and Cdc42 were 
obtained from Santa Cruz Biotechnology.   Primary antibodies were applied at a 1:100 
dilution for IHC.  Control IHC experiments were performed using the rabbit pre-immune, 
and GTPase-specific antibodies blocked with saturating levels of corresponding RhoA, 
Rac1 or Cdc42 peptide antigen. 
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CHAPTER III 
REGULATION OF KISS-1 METASTASIS SUPPRESSOR GENE EXPRESSION IN 
BREAST CANCER CELLS BY DIRECT INTERACTION OF TRANSCRIPTION 
FACTORS ACTIVATOR PROTEIN-2α AND SPECIFICITY PROTEIN-1* 
 
Overview 
KiSS-1 has been shown to function as a tumor metastasis suppressor gene and 
reduce the number of metastases in different cancers.  The expression of KiSS-1 or KiSS1, 
like other tumor suppressor, is commonly reduced or completely ablated in a variety of 
cancers via an unknown mechanism. Here we show that the loss of KiSS-1 expression in 
highly metastatic breast cancer cell lines correlates directly with the expression levels of 
two transcription factors, activator protein-2α (AP-2α) and specificity protein 1 (Sp1), 
which synergistically activate the transcriptional regulation of KiSS-1 in breast cancer 
cells. Although the KiSS-1 promoter contains multiple AP-2α binding elements, AP-2α-
mediated regulation occurs indirectly through Sp1 sites, as determined by deletion and 
mutation analysis. Overexpression of AP-2α into highly metastatic breast cell lines did not 
alter KiSS-1 promoter-driven luciferase gene activity.  However, co-transfection of AP-2α 
wild-type or the dominant negative form of AP-2 lacking its C-terminal DNA-binding 
domain, AP-2B, together with Sp1, increased KiSS-1 promoter activity dramatically, 
suggesting that AP-2α regulation of KiSS-1 transcription does not require direct binding to  
__________ 
*Reprinted with permission from “Regulation of KiSS-1 metastasis suppressor gene expression in breast 
cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1” by  
Mitchell, et al. (2006).  J Biol Chem 281, 51-58.  Copyright 2006 by ASBMB. 
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Sp1 to form transcription complexes at two tandem Sp1-binding sites of the promoter to 
activate KiSS-1 transcription.  Together, our results indicate that AP-2αand Sp1 are strong 
transcriptional regulators of KiSS-1 and that loss or decreased expression of AP-2α in 
breast cancer may account for the loss of tumor metastasis suppressor KiSS-1 expression 
and thus increased cancer metastasis. 
Introduction  
The vast majority of breast cancer deaths results from complications caused by 
tumor cell metastasis rather than as a consequence of the original tumor growth. Once 
tumorigenic cells enter into the vascular and lymphatic systems, they travel to peripheral 
regions where they invade tissues and form neoplasms. Metastasis is a process requiring 
detachment of cancer cells from the primary site, survival of sheer forces encountered in 
the circulation, migration to other organs, attachment to and invasion of tissues, 
proliferation of these cells at the secondary site, and finally the capacity to enlist 
neighboring capillaries to supply the tumor with nutrients as it develops (Pantel and 
Brakenhoff, 2004). Interference at any one of these steps can block this metastatic cascade 
thereby preventing the formation of metastatic tumor growths. Consequently, there is a 
growing interest in researching the metastatic process to identify possible ways to inhibit its 
progression. 
Metastasis suppressor genes, which inhibit the spread of cancers to secondary sites, 
have become the target of mounting clinical and basic cancer research. One such gene, 
KiSS-1 or KiSS1, was originally identified as a metastasis suppressor by microcell-
mediated transfer in melanoma lines, by which it was found to reduce tumor cell invasive 
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and migratory properties without affecting their tumorigenicity (Lee and Welch, 1997a). 
Since then, KiSS-1 has been shown to act as a potent anti-metastatic agent either by 
treatment using synthesized KiSS-1 peptide or upon ectopic expression in highly metastatic 
cells (Lee and Welch, 1997a; Masui et al., 2004; Ohtaki et al., 2001; Lee and Welch, 
1997b). Loss or reduced expression of KiSS-1 has been found in a variety of tumor 
metastasis, including breast cancer, bladder cancer, pancreatic cancer, and esophageal 
squamous cell carcinoma (Masui et al., 2004; Lee and Welch, 1997b; Ikeguchi et al., 2004; 
Sanchez-Carbayo et al., 2003). Together, these studies suggest that KiSS-1 is a human 
metastasis suppressor gene and that loss of KiSS-1 and its receptor may correlate with 
human tumor progression and metastasis. 
The KiSS-1 gene encodes a largely hydrophobic 145-amino acid protein highly 
expressed in the placenta (Ohtaki et al., 2001; Muir et al., 2001). The KiSS-1 gene product 
consists of a protein kinase phosphorylation domain, a secretory signal, and polyproline-
rich region, and a number of potentially important motifs for post-translational 
modifications (Muir et al., 2001; Lee et al., 1996). Independently, three groups discovered 
and isolated the 54-amino acid C-terminally amidated fragment of KiSS1 protein (amino 
acids 68–121), termed metastin and kisspeptin, respectively (Ohtaki et al., 2001; Kotani et 
al., 2001). The function of KiSS-1 peptide is mediated through interaction with the 
membrane-bound G-protein-coupled receptor, GPCR54, a close relative of the galanin 
receptor (Ohtaki et al., 2001; Masui et al., 2004; Kotani et al., 2001; Lee et al., 1999; 
Clements et al., 2001). C-terminal amidation of the KiSS-1 peptide leads to strong binding 
with GPCR54, initiating a series of cellular changes, including increased intracellular 
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[Ca2+] and inositol 1,4,5-trisphosphate release, as well as morphological changes, such as 
up-regulating focal adhesion and stress fiber formation (Ohtaki et al., 2001; Muir et al., 
2001; Kotani et al., 2001; Stafford et al., 2002). Collectively, these signaling events inhibit 
chemotaxis and invasion, reducing the incidence of tumor metastasis (Ohtaki et al., 2001; 
Lee and Welch, 1997b; Stafford et al., 2002). However, while much has been learned about 
the possible physiological effects of KiSS-1 expression in cancer cells, the mechanism 
controlling KiSS-1 transcriptional regulation is still unknown as is the underlying reason 
for its loss during metastatic progression. 
As breast cancer cells become increasingly metastatic, expression levels of different 
genes, contributing to cell cycle, tumor cell invasion, and migratory properties, are altered. 
Genes commonly found up-regulated in breast cancer, including cyclin D1, c-myc, and 
MMP-9,  mediate behavioral and proliferative changes that stimulate oncogenesis, whereas 
the loss of c-Kit or p53 may also encourage an increased metastatic phenotype, because 
they are no longer present to block formation of neoplasms (Gillet et al., 1996; Yu et al., 
2001; Wang et al., 2005; Stuelten et al., 2005; Smith et al., 2003; Huang et al., 1998). 
Transcription factors that modulate the expression of oncogenes play important roles 
during tumorigenesis and metastasis. AP-2α, is a 52-kDa transcription factor, regulates 
genes that are important during development and metastatic processes (Zhang et al., 1996; 
Bar-Eli, 1999).  Genes under AP-2-modulated transcriptional regulation contain the 
consensus palindromic sequence 5'-GCCNNNGGC-3' and have a variety of cellular 
functions, such as human proenkephalin, plasminogen activator inhibitor type I, c-erbB-2, 
c-Kit, thrombin receptor, and vascular endothelial growth factor (Huang et al., 1998; Bauer 
 
 21
et al., 1994; Hyman et al., 1989; Descheemaeker et al., 1992; Bosher et al., 1995; Tellez et 
al., 2003). Located on the short arm of chromosome 6, AP-2 protein contains a DNA-
binding domain, a protein kinase A phosphorylation site, and a transactivation domain 
(Gaynor et al., 1991; Williams and Tjian, 1991). A naturally occurring splice variant, AP-
2B, lacks the DNA-binding domain, thus enabling it to function as a dominant negative 
form of the AP-2α protein (Gershenwald et al., 2001). AP-2 has been shown to regulate 
neoplasm development by directly and indirectly regulating gene expression. In addition to 
inducing or repressing activity of cancer-related genes at their promoter, AP-2α can 
physically interact with oncogenes, such as β-catenin, DEK, and Pax6, and is thereby 
directly involved in tumorigenesis and development (Turner et al., 1998; Zhang et al., 
2003; Sivak et al., 2004; Li and Dashwood, 2004; Campillos et al., 2003; Nottoli et al., 
1998). Loss of AP-2 is common in breast cancer and in many other cancers, resulting in the 
loss of regulation of multiple oncogenes and increased tumorigenesis.  Sp1 has also been 
shown to regulate genes involved in tumorigenesis, including the up-regulation of both 
hepatocyte growth factor receptor and vascular endothelial growth factor (Liang et al., 
2004; Finkenzeller et al., 2004; Abdelrahim et al., 2004; Yao et al., 2004). Additionally, 
Sp1 can directly interact with the c-Jun transcription factor to modulate the up-regulation of 
vimentin, a protein commonly found misregulated in metastatic tumors (Wu et al., 2003). 
Sp1 itself has been shown to be a useful molecular marker is gastric cancer and Sp1 
expression has been shown to be closely associated with patient survival rate (Wang et al., 
2005, Wang et al., 2003).  Here, we report that the expression of KiSS-1 metastasis 
suppressor gene in breast cancer cells is directly correlated with the expression of 
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transcription factors AP-2α and Sp1, and that AP-2α and Sp1 synergistically activate the 
transcriptional regulation of KiSS-1 in breast cancer cells. Furthermore, we demonstrate 
that KiSS-1 expression is modulated by AP-2α through direct interaction with the 
transcription factor Sp1 at two tandem Sp1-binding sites rather than via interaction with the 
consensus AP-2-binding sites of KiSS-1 promoter. These results offer a mechanism for the 
loss of KiSS-1 gene expression commonly seen in metastatic breast cancers and provide 
another molecular mechanism by which AP-2α and Sp1 transcription complex modulates 
tumorigenesis and tumor progression. 
Endogenous KiSS-1 Expression in Breast Cancer Cell Lines Correlates with AP-2α 
Expression Levels 
We and other laboratories have reported that KiSS-1 expression is lost in highly 
metastatic breast cancer cells. To determine if loss of the transcription factor AP-2α and 
Sp1 was directly or inversely associated with loss of KiSS-1, the expression levels of AP-
2α and Sp1 levels in both highly metastatic and non-metastatic breast cells were compared 
with the expression of KiSS-1 (Figure 2). Due to the lack of a specific and effective KiSS-1 
antibody, KiSS-1 expression level in the breast cell lines was quantitated using RT-PCR 
and normalized to the β-actin level within each sample. The relatively non-metastatic breast 
cell line, MCF-7, showed dramatically higher -fold expression as compared with the more 
metastatic breast tumor cell lines (T47D, MDA-231, and MDA-435). Similarly, Western 
blot analysis demonstrated that AP-2α expression was lost or barely detectable in the 
metastatic cell lines, MDA-231 and MDA-435 (Figure 2). The expression levels of Sp1 
were also examined in these cells.  As shown in Figure 2 (bottom), Sp1 expression was 
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Figure 2:  Western Blot and RT-PCR Analysis Correlating KiSS-1 Expression and 
AP-2α and Sp1 in Breast Cancer.  RT-PCR and immunoblot analysis for the expression 
of KiSS-1, AP-2α and Sp1 in breast cancer cell lines.  Highly metastatic breast cancer cell 
lines (T47D, MDA-231 and MDA-435) expressed low to undetectable levels of KiSS-1 
and AP-2α, while the less metastatic MCF-7 cell expressed appreciably higher levels of 
both.   
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slightly decreased in the metastatic cancer cell lines (Figure 2). Together, these data 
suggest that the expression of KiSS-1 was correlated very well with the expression levels 
of the two transcription factors, especially AP-2α, in breast cancer cells. To further confirm 
that KiSS-1 expression is regulated by AP-2α and Sp1, we reintroduced both AP-2α and 
Sp1 into these cells (Figure 3). Activation of the KiSS-1 promoter by overexpression of 
AP-2α and Sp1 was enhanced considerably from 4- to 27-fold depending on the cell line. 
Although it is not clear why transfection of AP-2α and Sp1 strongly activate KiSS-1 
promoter construct in MCF-7 cells where these factors are expressed at higher endogenous 
level, we speculate that overexpression of these two proteins have an additive effect on the 
activation of the KiSS-1 promoter construct with the endogenous factors. Therefore, we 
concluded that the loss of both AP-2α and Sp1 strongly and directly correlated with the 
loss of KiSS-1 expression in breast cancer cells. 
Identification of the Regulatory Region of the KiSS-1 Gene by AP-2α and Sp1 
Regions of sequence conservation, found between humans and mice or rats, are 
commonly used as an indicator of whether a sequence, such as a promoter sequence, may 
be maintained over the course of evolution to serve an important molecular function, such 
as the binding of transcription factors necessary for transcriptional regulation of that gene. 
To understand how AP-2 and Sp1 regulate the expression of KiSS-1 gene, we examined 
and analyzed the potential regulatory regions of KiSS-1 gene among different species 
(Figure 4). As sequence homology appeared to drop sharply after the first 1.2 kb, we 
initially focused our promoter analysis within this region, which was then cloned into a  
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Figure 3:  Co-Transfection of AP-2α and Sp1 Leads to Increased KiSS-1 Expression.  
Significant fold up-regulation of a KiSS-1 promoter-driven luciferase expression was 
observed in all breast cancer cell lines when co-transfected with both AP-2α and Sp1. 
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A.
1.2Kb KiSS-1
1.0Kb KiSS-1
292bp KiSS-1
156bp KiSS-1
B.
 
 
Figure 4:  Identification of Regulatory Regions of KiSS-1 by AP-2α and Sp1 
Transcription Factors.  (A) Sequence conservation of the KiSS-1 promoter regions.  
Human sequences were aligned to that from different species, including chimp, dog, 
mouse, rat, chicken, fugu, and zebra fish.   Significant similarity was observed up to nearly 
1.2 Kb, but the highest homology was seen within the first 600 bp of this regulatory region.  
Sp1A/B indicates two conserved Sp1 sites.  (B) Schematic of regulatory region of KiSS-1 
depicting the potential AP-2α (unfilled ovals) and Sp1 (filled circles) transcription factor 
binding elements.  
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luciferase reporter vector. Sequence analysis of the highly conserved 400-bp region (∼70% 
homology) located 5' proximal to the KiSS-1 coding region contains three consensus AP-2α  
binding elements flanked by multiple Sp1 sites (Figure 4). Given that the KiSS-1 promoter, 
much like other AP-2-regulated genes, contains multiple AP-2αbinding elements and a 
regulatory region rich in GC-content, it became a likely candidate gene regulated by AP-
2/Sp1 complexes in tumor cells. 
AP-2α and Sp1 Synergistically Activate KiSS-1 Transcription 
To determine whether AP-2 and Sp1 were involved in transcriptional regulation of 
the KiSS-1 tumor metastasis suppressor gene, luciferase reporter constructs bearing 1.2-kb 
region of the KiSS-1 promoter were transfected into breast cell lines along with AP-2, Sp1, 
or both.  Using β-galactosidase to normalize for transfection efficiencies, we analyzed the 
luciferase activity driven by the KiSS-1 promoter.  Results showed that while KiSS-1-
luciferase activity was only slightly increased upon overexpression of either AP-2 or Sp1 in 
MCF-7 cells, KiSS-1 promoter activity was increased more than 10-fold in cells co-
transfected with both AP-2 and Sp1 constructs (Figure 5).   Additionally, luciferase 
constructs bearing serial deletions of the KiSS-1 promoter were assayed for activation upon 
co-expression of AP-2α and Sp1 to determine which regions of the KiSS-1 promoter 
modulated transcriptional activation by AP-2α and Sp1.  As shown in Figure 5, the 292-bp 
KiSS-1 promoter luciferase construct was synergistically activated by co-transfection of 
AP-2α and Sp1 similar to results using the 1.2-kb and 1.0-kb luciferase constructs, whereas 
the 156-bp KiSS-1 promoter construct showed significantly less activation (Figure 5), 
suggesting that the 292-bp promoter contains the regulatory elements essential for 
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Figure 5:  Co-Transfecton of AP-2α and Sp1 Leads to Increased KiSS-1 Promoter 
Activation.  Activation of different KiSS-1 promoter-derived luciferase constructs by AP-
2α and Sp1 transcription factors.  Luciferase assays using serial truncation of KiSS-1 
promoter demonstrate that the region modulated by Sp1 and AP-2α lies within -292 bp of 
the sequence, as this AP-2α modulated transcriptional activation is ablated when assaying 
shorter regions of the KiSS-1 promoter sequence.   
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transcriptional regulation by the AP-2α and Sp1 complex and that the promoter region 
sensitive to AP-2α and Sp1 control intervenes between these sites (156 and 292-bp). 
AP-2α-activated KiSS-1 Transcription Is Independent of Direct Promoter Binding 
But through Interaction with Sp1 at Two Consensus Sp1 Sites 
To understand the molecular mechanism of KiSS-1 gene transcriptional regulation 
by AP-2α and Sp1, we examined whether direct DNA binding of AP-2α and Sp1 is 
essential for the remarkable activation of KiSS-1 promoter. AP-2 and Sp1 constructs 
lacking the DNA-binding domains of each transcription factor (AP-2B and Sp1-∆DBD) 
were co-transfected into MDA-435 and MCF-7 cells with the 292-bp KiSS-1 promoter 
luciferase construct and measured for luciferase activity (Figure 6). As expected, dominant 
negative Sp1-∆DBD failed to activate KiSS-1 promoter-mediated luciferase activity when 
co-transfected with AP-2α. However, AP-2B, the truncated AP-2α lacking the C-terminal 
DNA-binding domain, significantly increased luciferase activity to the same degree as the 
wild-type form of AP-2 when co-transfected with Sp1 transcription factor. These results 
suggest that the DNA-binding domain of AP-2α is not necessary in modulating KiSS-1 
transcriptional activity in human breast cancer cells.  To determine the discrete 
transcriptional binding sites essential in mediating AP-2α/Sp1 transcriptional regulation of 
KiSS-1, we generated additional truncation mutants of 150, 190, 230, 260, and 300-bp in 
the luciferase reporter plasmid, as shown in Figure 7. These truncated reporter plasmids 
were co-transfected with AP-2α and Sp1 in breast cell lines for further luciferase analysis. 
As shown in Figure 7, the promoter region between +230 and +260 demonstrated the 
greatest sensitivity to AP-2α/Sp1 transcription factors. Co-transfection of AP-2α and Sp1  
 
 30
 
0
5
10
15
20
25
30
35
MCF-7
MDA-435
SP
1
Sp
1∆D
BD
AP
-2
AP
-2
B
AP
-2
 +
Sp
1
AP
-2
 +
Sp
1∆D
BD
AP
-2
 B
+S
p1
Fo
ld
 In
cr
ea
se
 o
f K
iS
S-
1 
Ex
pr
es
si
on
(R
el
at
iv
e 
Lu
c.
 A
ct
iv
ity
)
Fo
ld
 In
cr
ea
se
 o
f K
iS
S-
1 
Ex
pr
es
si
on
(R
el
at
iv
e 
Lu
c.
 A
ct
iv
ity
)
 
Figure 6:  Activation of KiSS-1 Expression by AP-2α is Independent of Direct 
Promoter Binding.  Activation of KiSS-1 promoter activity by wild-type AP-2α, Sp1, 
DNA-binding deficient mutants AP-2α (AP-2B) and Sp1 (Sp1∆DBD) using luciferase 
assays.  AP-2α and Sp1 synergistically enhances KiSS-1 activation, as does the C-terminal 
deletion mutant of AP-2 (AP-2B) when co-transfected into MDA-435 and MCF-7 breast 
cell line, while co-transfection of the DNA-binding domain deletion mutant of Sp1 
(Sp1∆DBD) failed to activate the KiSS-1 promoter.    
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Figure 7:  Promoter Region Between +260 and +230 Modulates AP-2α and Sp1 
Transactivation.  Additional serial deletions of the KiSS-1 promoter of -300, -260, -230, -
190, and -150 bp in length were assayed in luciferase experiments, demonstrating that the 
region most notably modulated by Sp1 and AP-2α lies between -230 and -260 bp which 
consists of two highly conserved Sp1 putative binding sites (Sp1-A and Sp1-B).   
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significantly stimulates the activity of the 260-bp KiSS-1-Luc, similar to that exhibited by 
the 300-bp KiSS-1-Luc construct, but did not contain any putative AP-2 sites.  The 260-bp 
KiSS-1-Luc does, however, contain two consensus Sp1 sites in tandem, identified as Sp1A 
and Sp1B (Figure 7). To further determine if these two Sp1 sites were essential in 
mediating the transcriptional modulation of the KiSS-1 promoter by AP-2α and Sp1, 
constructs of single targeted deletion (mutant Sp1-A or mutant Sp1-B) at these two sites as 
well as double deletions (mutant Sp1-A/B) at both sites of the KiSS-1 promoter were 
generated and tested in luciferase assay (Figure 8). Results showed that mutation at either 
Sp1 site rendered the KiSS-1 promoter insensitive to the regulation of AP-2α and Sp1 
transcription factors in MCF-7 cells (Figure 8), suggesting that the two Sp1 sites are 
essential for the observed regulation of KiSS-1 promoter by AP-2α and Sp1 transcription 
factors. 
Sp1 and AP-2α Form a Complex at the Sp1 Sites of KiSS-1 Promoter 
To determine the complex formation of Sp1 and Ap-2α at the two Sp1 sites in 
mediating AP-2α/Sp1 regulation of the KiSS-1 gene transcription, gel mobility shift 
analysis (EMSA) was performed using the GC-rich sequence spanning +230 to +260 of the 
KiSS-1 promoter (Figure 9).   Results of EMSA using AP-2α and Sp1-transfected MCF-7 
cells showed that both Sp1 and Sp3 bind to the 30-bp γ-32P-labeled probe (lanes 2–4), 
however this DNA-protein interaction was abrogated in the presence of unlabeled 
competitor (lane 5). The negative control showing labeled probe in the absence of nuclear 
extract is shown in lane 1.  Upon addition of a Sp1-specific antibody, the migration of the 
DNA-protein complex was sterically hindered by the bound antibody, resulting in a  
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Figure 8:  Targeted Mutation of Two Consecutive Sp1 Sites Leads to AP-2α/Sp1 
Promoter Insensitivity.  Targeted mutations of the two Sp1 sites illustrated that both sites 
(Sp1-A and Sp1-B) were essential in mediating the AP-2α/Sp1-modulated transactivation 
of the KiSS-1 promoter.   
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Figure 9:  EMSA Analysis Shows Sp1 Binding at KiSS-1 Promoter.  EMSA assay using 
cells transfected with AP-2α and Sp1, demonstrates two Sp1 binding elements (Sp1A and 
Sp1B) are binding sites for Sp1/AP-2 complexes.  This 30bp sequence was used in EMSA, 
and lane 3 indicated Sp1-specific antibody supershifted probe, whereas the Ig-G negative 
control showed no shift (lane 4).  Additionally, bands resulting from Sp1-DNA complex 
are greatly reduced upon addition of unlabeled 100X competitor (lane 5).  Incubation of 
anti-AP-2 antibody results in loss of SP1-DNA complexes indicating a competition for 
binding (lane 6). 
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supershifted  third band (lane 3). However, the ability to supershift the labeled probe was 
specific for the Sp1 antibody, because the antibody for IgG failed to exhibit any ability to 
complex with this protein-bound probe (negative control, lane 4). Incubation of the labeled 
promoter fragment with anti-AP-2 antibody resulted in a diffusion of the bands formed by 
the Sp1-DNA complex, indicating that AP-2 may also bind to this complex. To further 
demonstrate that AP-2α exists in the Sp1-DNA complex, we performed chromatin 
immunoprecipitation (ChIP) assays using sheared DNA isolated from AP-2α/Sp1 co-
transfected MCF-7 cells. Overnight immunoprecipitation of chromatin-bound DNA using 
antibodies to Sp1, AP-2, and IgG was followed by PCR using primers that amplified the 
100-bp region spanning the length of the two Sp1 sites (Sp1-A and Sp1-B) (Figure 10A). 
As shown in the ChIP assays (Figure 10B), anti-Sp1 and anti-AP-2 antibodies were capable 
of immunoprecipitating the KiSS-1 promoter fragment containing the two Sp1 sites (lanes 
4 and 5), however, immunoprecipitation using anti-IgG failed to produce a PCR product 
(Figure 10B, lane 3). 
AP-2α Interacts Directly with Sp1 at an N-terminal Domain of the Protein 
Our data indicate that both AP-2α and AP-2α C-terminal deletion mutant (AP-2B) 
lacking the DNA-binding domain synergistically enhance Sp1-mediated activation of 
KiSS-1, suggesting that the effect of AP-2α is through the interaction with Sp1, 
independent of its ability to directly bind the AP-2 consensus sites of the KiSS-1 promoter. 
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Figure 10:  Chromatin Immunoprecipitation Shows Binding of Sp1 and AP-2α to 
KiSS-1 Promoter.  (A)  Schematic of the KiSS-1 promoter region containing two Sp1 
binding elements (Sp-1A and Sp-1B) analyzed by ChIP assay.  PCR primers (gray bars) 
amplified a 100 bp region ranging from-188 to -288.  (B)  ChIP using MCF-7 cell lysates 
transfected with AP-2α and Sp1.  Chromatin was immunoprecipitated using antibodies to 
Sp1 and AP-2 (lane 4 and lane 5).  Anti-IgG was used as a negative control (lane 3).  The 
1.2 Kb KiSS-1 promoter was used as a positive control for the PCR (lane1).   
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To demonstrate the N-terminal region of AP-2α without the C-terminal DNA-binding 
domain directly interacts with Sp1 in the cell, MCF-7 breast cancer cells were co-
transfected with Sp1, AP-2, and AP-2B or control vector. Cell lysates were incubated with 
immunoblotted for the alternate antibody (Figure 11). Immunoprecipitation of cell lysates 
that overexpress AP-2α or AP-2B by anti-AP-2 antibody demonstrated the presence of Sp1 
protein in the immunocomplexes (Figure 11A, lanes 2 and 3) as compared with the vector 
control (lane1).  Conversely, both AP-2α and AP-2B were immunoprecipitated with the 
Sp1 antibody (Figure 11B, lanes 2 and 3) in cells that overexpressed either protein, 
whereas vector-transfected cell lysate did not show any immunoreactivity (lane 1). Relative 
amounts of AP-2α and Sp1 levels are also shown (Figure 11, C and D). These results 
demonstrate the direct interaction of the N-terminal region of AP-2α with the Sp1 
transcription factor in breast cell lysate. 
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Figure 11:  Direct Interaction of AP-2α with Sp1 Transcription Factor.  (A)  Co-
immunoprecipitations of Sp1 with wild-type AP-2α and mutant AP-2B using the N-
terminal AP-2α specific antibody in lysates expressing AP-2α (lane 2), AP-2B (lane 3) and 
vector (lane 1).  The protein complexes were immunoblotted with Sp1 antibody.   (B)  
Association of AP-2α and DNA-binding domain mutant (AP-2B) with Sp1 in transfected 
MCF-7 cells.  Stably transfected MCF-7 cells expressing AP-2α (lane 2), AP-2B (lane 3), 
and vector only (lane 1) were co-immunoprecipitated with specific Sp1 antibody and 
immunoblotted with antibody against the N-terminal domain of AP-2α.  Western blot 
analysis showing AP-2 (C) and Sp1 (D) expression in transfected MCF-7 lysates used in 
co-immunoprecipitation assays. 
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 Discussion 
 Treatment of metastatic breast cancer cells with synthetic KiSS-1 peptide as well as 
ectopic overexpression of KiSS-1 in these cells has been shown to significantly alter 
overall cellular morphology and behavior, thus hindering metastasis (Lee and Welch, 
1997a; Ohtaki et al., 2001; Muir et al., 2001; Kotani et al., 2001). The expression of KiSS-
1, like other tumor suppressors, is commonly reduced or completely ablated in a variety of 
different cancers (Masui et al., 2004; Lee and Welch, 1997b; Ikeguchi et al., 2004; 
Sanchez-Carbayo et al., 2003). As the level of KiSS-1 expression has been correlated to 
patient survival and severity of metastatic development, KiSS-1 has become an effective 
biomarker for the metastasis of these cancers (Sanchez-Carbayo et al., 2003). In this study, 
we demonstrate that the expression of KiSS-1 is directly  correlated with the expression 
level of another known tumor-suppressor, the AP-2α transcription factor. Highly metastatic 
breast cell lines exhibit little to no AP-2α expression, paralleling the loss of the KiSS-1 
gene in these cells. Additionally, we found that AP-2α and Sp1 synergistically activate the 
transcriptional activation of KiSS-1 promoter in multiple breast cancer cell lines via direct 
interaction of these two transcription factor at two tandem Sp1-binding sites of the 
promoter. 
Although MCF-7 exhibited higher levels of endogenous AP-2α and Sp1 expression 
relative to the other breast lines (Figure 2), the significant increase in KiSS-1 promoter 
activation seen upon transfection of both transcription factors (Figure 3) is likely due to the 
additive effect caused by the overexpression of these proteins in the same cells transfected 
with the KiSS-1 promoter construct.  The KiSS-1 promoter was found to contain multiple 
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AP-2α-binding sites, all of which were flanked by clusters of Sp1 sites; furthermore, this 
region was rich in G-C content, making KiSS-1 a likely candidate for regulation by AP-2α 
and Sp1 complex. Serial truncations of the KiSS-1 regulatory region demonstrated that the 
AP-2α/Sp1 regulation was mediated through a region of the promoter between +230 and 
+260-bp with only two putative Sp1 consensus sites. The ability of Sp1 to bind to this 
discrete 30-bp sequence was confirmed in EMSAs in which an Sp1-specific antibody could 
bind this protein-bound promoter segment as evidenced by its ability to supershift the 
complex. EMSA results for anti-AP-2α-antibody incubated nuclear extracts showed a 
diffusion of the bands formed by the Sp1-DNA complex, thus indicating that AP-2α may 
also bind this complex. Additional chromatin immunoprecipitation using the region of the 
promoter carrying the two tandem Sp1 sites demonstrated that both AP-2α and Sp1 were 
capable of promoter interaction.  Mutation analysis at these two putative Sp1 sites further 
demonstrated the binding of the AP-2α/Sp1 complex at these two sites and the essential of 
these two sites in AP-2- and Sp1-mediated transcriptional activation of KiSS-1. Although 
AP-2α is necessary to mediate transcriptional regulation of the KiSS-1 promoter, our 
EMSA results, luciferase-reporter assays using a dominant negative form of AP-2α that 
lacks the C-terminus DNA-binding domain, and the co-immunoprecipitation assays 
demonstrated that the N-terminal domain of AP-2α forms a protein complex to regulate 
transcriptional activation of KiSS-1 and that the role of AP-2α is independent of its 
promoter-binding ability.  Taken together, our data suggest a possible model for 
transcriptional activation of KiSS-1 in breast cells (Figure 12). In normal cells, in which 
AP-2α is regularly expressed, the N-terminal region of AP-2α interacts with Sp1, which 
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Figure 12:  Proposed Model for the Regulatory Mechanism of KiSS-1 Expression in 
Both Normal and Metastatic Cancer.  Proposed model for the regulatory mechanism of 
KiSS-1 expression in both normal and metastatic breast cancer.  Our data supports that 
when AP-2α is regularly expressed as it is in normal breast tissues, the N-terminal region of 
AP-2α directly interacts with Sp1 to transactivate the KiSS-1 promoter and KiSS-1 
expression.  However, loss or reduced expression of AP-2α leads to the disruption of the 
AP-2α/Sp1 transcriptional complexes, and consequently, the loss or reduced expression of 
KiSS-1 suppressor gene in metastatic cancer cells.   
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binds to the two-consensus Sp1-binding sites. The AP-2α and Sp1 complex initiates 
transactivation of the KiSS-1 promoter and lead to the expression of KiSS-1 gene (Figure 
12). Alternatively, when AP-2α expression is lost, as commonly found in many cancer 
types, depletion of AP-2α/Sp1 transcription factor complex leads to a loss of KiSS-1 
transcriptional activation (Figure 12). Contrary to conventional transcriptional regulation 
by AP-2α, in which AP-2α recognizes and binds to its consensus DNA-binding site 5'-
GCCCNNNGGC-3' (Williams and Tjian, 1991), our results demonstrate a novel 
mechanism in which AP-2α regulation is mediated through two tandem Sp1 elements 
located between +230 to +260-bp and requires direct protein-protein interaction of the N-
terminal portion of AP-2α with Sp1 protein.  KiSS-1 was originally identified to reduce 
melanoma metastasis by 95% using microcell-mediated transfer of chromosome 6 (Lee and 
Welch, 1997a). Although KiSS-1 was later accurately mapped to chromosome 1q32-q41, it 
was believed that this region of the chromosome 6 contained a key, and as yet, unidentified 
KiSS-1 regulator that activated KiSS-1 expression upon transfer into melanoma cells. 
Interestingly, AP-2α is located in the short arm of chromosome 6, the exact region believed  
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to regulate KiSS-1; therefore, AP-2α may in fact be the missing KiSS-1 regulatory factor.  
Our data strongly establish a correlation between the loss of the AP-2α transcription factor 
and loss of the KiSS-1 metastasis suppressor in breast cancer cell lines. Loss of AP-2α has 
been implicated in the development of many other cancers besides invasive breast 
carcinomas, including colorectal, prostate, and ovarian cancer, renal cell carcinoma, and 
melanoma. Because KiSS-1 expression has also been found to be reduced in many of these 
same cancers, it is possible that KiSS-1 expression in these tissues is similarly reliant on 
the interaction of AP-2α with Sp1 and that the loss of AP-2α is paralleled by the loss of 
KiSS-1 expression, causing such cells to effectively lose another barrier to metastatic 
development. For this reason, our current studies are extending these observations of the 
role of AP-2α in mediating KiSS-1 expression in other cancers to identify similar 
mechanisms underlying the loss of KiSS-1 expression in such tissues and cancers. 
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CHAPTER IV 
REGULATION OF KISS-1 METASTASIS SUPPRESSOR GENE EXPRESSION IN 
MELANOMA BY SPECIFICITY PROTEIN-1 AND COACTIVATOR DRIP-130 
 
Overview 
The loss of the metastasis suppressor gene, KiSS-1 or KiSS1, has been strongly 
correlated to the progression of metastases in numerous types of cancers.  The mechanism 
through which KiSS-1 is lost during metastasis, however, is still not completely known.  
Previous studies have shown that genetic material on human chromosome 6q16.3-q23 is 
essential for KiSS-1 expression in normal tissues.  Additionally, microcell-mediated 
transfer of this chromosome in cancerous tissue results in rescued expression of KiSS-1 and 
reduced metastatic phenotype.   Here, we show that loss of Sp1-coactivator protein DRIP-
130, which is encoded by human chromosome 6q16.3-q23, results in reduced KiSS-1 
promoter activation in highly malignant melanoma cells.  Co-expression of Sp1 and DRIP-
130 not only rescues KiSS-1 expression, but also induces an inhibition of the invasive and 
migratory behavior in highly metastatic melanoma cells, similar to the overexpression of 
KiSS-1 metastasis suppressor gene in those cells.   Furthermore, we demonstrate that KiSS-
1 expression is regulated by Sp1 elements within the first 100-bp region of the KiSS-1 
promoter and that targeted deletion of a single GC-rich region spanning +93 to +58 
interrupts Sp1- and DRIP-130-modulated transcriptional control of KiSS-1 expression.  
Our results thus suggest that DRIP-130 is a key regulator in KiSS-1 transactivation in 
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normal tissue, and that the loss of DRIP-130 expression, as a result of the gross loss of 
human chromosome 6q16.3-q23, provokes increased tumor metastasis.  
Introduction 
Metastasis is an involved process in which cancer cells spread through the 
circulatory system, adhere and invade new tissues and then develop as secondary cancers 
(Pantel and Brakenhoff, 2004).  In the past decade, several genes have been identified 
which interfere in the metastatic cascade, thus inhibiting cancer metastasis; such genes are 
consequently called metastasis suppressors (Steeg et al., 2003).  As these genes were only 
recently identified, the mechanisms by which they inhibit the progression and metastasis of 
cancers largely remain a mystery, as does the regulation of their expression in both normal 
and tumorigenic tissues.  KiSS-1, or KiSS1, is a precursor for secreted peptide ligands for a 
G-protein coupled receptor, named hGPR54 (Kotani et al., 2001), or hOT7T175 (Ohtaki et 
al., 2001), or AXOR12 (Muir et al., 2001) or KiSS1 receptor (Stafford et al., 2002).  The 
active peptide ligands are designated as Metastin (Ohtaki et al., 2001) or Kisspeptins 
(Kotani et al., 2001).  Although KiSS1 and its G-protein coupled receptor have been shown 
to suppress tumor metastasis in different tumors, including breast tumor, lung tumor, and 
melanoma (Lee and Welch, 1997a; Lee and Welch, 1997b), the mechanism for KiSS-1 
suppression is still unknown.  Recent studies suggest that KiSS-1 activates G-protein 
mediated PLC-Ca2+ signaling pathways in different cell types as well as ERK and p38 
MAPK pathways to inhibit cell mobility, migration, and invasion in vitro (Ohtaki et al., 
2001; Stafford et al., 2002; Kotani et al., 2001; Muir et al., 2001; Yan et al., 2001). 
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Microcell-mediated transfer of highly metastatic melanoma was initially used to 
identify KiSS-1 as a metastasis suppressor gene, as it was shown to reduce invasive and 
migratory properties without affecting tumorigenicity (Lee and Welch, 1997b).  Similar to 
that of other known metastasis suppressors, the expression of KiSS-1 is commonly found to 
be inversely correlated to the degree of cancer metastasis.  Since its identification, loss of 
KiSS-1 expression has been shown to be a good indicator for the progression of several 
types of cancers, including breast, melanoma, pancreatic, bladder, and esophageal 
squamous cell carcinoma (Masui et al., 2004; Lee and Welch, 1997a; Ikeguchi et al., 2004; 
Sanchez-Carbayo et al., 2003).  Additionally, treatment with synthesized KiSS-1 peptide, 
as well as the induced overexpression of KiSS-1 in vitro, effectively reduces invasive and 
migratory properties of cancer cells (Lee and Welch, 1997a; Masui et al., 2004; Ohtaki et 
al., 2001; Stafford et al., 2002; Lee and Welch, 1997b).   As previously published, the 
KiSS-1 promoter is highly GC-rich and computational analysis of this region revealed 
multiple Sp1 sites, which our lab has shown to be necessary, along with the transcription 
factor AP-2α, to promote KiSS-1 transcriptional activation in breast cancer (Mitchell et al., 
2006).  Our earlier data supported a model by which the loss of AP-2α which accompanies 
the progression of multiple forms of cancer resulted in the overall loss of KiSS-1 
expression in breast cancer cells and the loss of the metastatic inhibition mediated by KiSS-
1 (Mitchell et al., 2006).  Recent evidence suggests the possible involvement of KiSS-1 
regulatory genes in chromosome 6 (6q16.3-q23) in tumor metastasis suppression (Miele et 
al., 2000; Shirasaki et al., 2001).  Deletion of 6q16.3-q23 and loss of heterozygosity in that 
region correlated with decreased KiSS-1 expression, suggesting that KiSS-1 is regulated by 
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a possible regulatory factor in that region of the chromosome (Miele et al., 2000; Shirasaki 
et al., 2001).  One of the major objectives of our current study is to identify the upstream 
regulator(s) of KiSS-1 which are encoded by chromosome 6q16.3-q23.  DRIP-130, like 
AP-2α, is localized to the short arm of human chromosome 6, the region believed to encode 
the regulatory factor(s) of KiSS-1 (Goldberg et al., 2003).  DRIP-130, also known as 
CRSP130, is one of 15 subunits which compose the transcriptional cofactor complex 
CRSP/Mediator, which is required for transcriptional activation by Sp1 (Ryu et al., 1999; 
Ryu and Tjian, 1999; Taatjes et al., 2004).    It has also been suggested that DRIP-130 itself 
acts as a metastasis suppressor, as its expression in clinical samples of melanomas is 
directly correlated with other metastasis suppressors as detected by quantitative real-time 
reverse-transcription PCR (Goldberg et al., 2003).   
In this study, we provide data to support a mechanism by which Sp1 strongly 
regulates transcriptional activation of the KiSS-1 promoter and KiSS-1 gene expression by 
interacting with the DRIP-130 subunit of the CRSP cofactor complex.  In human metastatic 
melanomas, the loss of the region in chromosome 6 (6q16.3-q23), which encodes the 
DRIP-130 subunit of the CRSP coactivator complex, results in the consequent loss of 
KiSS-1 metastasis suppressor gene expression.  Additionally, we report that re-introduction 
of DRIP-130 in highly metastatic melanoma cells induces higher KiSS-1 expression, and 
that coexpression of Sp1 and DRIP-130 decreases the invasive and migratory properties of 
the metastatic melanoma cells.  Furthermore, we demonstrate that KiSS-1 expression is 
modulated by Sp1 elements within the first 100-bp region of the KiSS-1 promoter and that 
targeted deletion of a single GC-rich region spanning +93 to +58 of the promoter interrupts 
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Sp1- and DRIP-130-modulated transcriptional control of KiSS-1 expression.  Therefore, 
our data provides a regulatory mechanism for the loss of KiSS-1 gene expression 
commonly seen in metastatic melanomas and correlates it with the gross loss of genetic 
material on human chromosome 6q16.3-q23 which accompanies this loss and leads to 
heightened tumor metastasis.   
Identification of the Regulatory Region of KiSS-1 Promoter by Sp1 and its 
Coactivator DRIP-130 in Melanoma  
The full-length human KiSS-1 promoter has a high GC-content and computer 
analysis has indicated the presence of multiple Sp1 sites throughout the sequence.  One of 
the most GC-rich regions of the KiSS-1 promoter, containing more than 10 overlapping 
putative Sp1 sites, is found within the first hundred bases of the KiSS-1 start site (see 
Figure 13A).  Recent evidence has revealed that the transcription factor, Sp1, requires the 
presence of other cofactors for proper assembly on Sp1-modulated promoters, such as the 
CRSP complex (Ryu et al., 1999).   Our recent study has demonstrated that Sp1, together 
with AP-2α, regulates KiSS-1 transcriptional activity in breast cancer cells (Mitchell et al., 
2006).  To determine whether the transcriptional effect of Sp1 on KiSS-1 expression in 
melanoma is modulated by the Sp1 co-activator, DRIP-130, we examined the effects of 
Sp1 and DRIP-130 on the transcriptional activation of KiSS-1 promoter using a series of 
KiSS-1 promoter regions subcloned into the luciferase reporter gene constructs (see Figure 
13A).  Luciferase assays were carried out as previously described and normalized using β-
galactosidase levels (Mitchell et al., 2006).  As shown in Fig. 13B, whereas single 
transfections of DRIP-130 and Sp1 had no effect on activation of the first 1Kb region of the 
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Figure 13:  The KiSS-1 Promoter Contains Multiple Overlapping Sp1 Sites Regulated 
by DRIP-130 and Sp1.  (A)  Schematic representation of human KiSS-1 promoter-driver 
luciferase constructs containing 35bp cluster of overlapping putative Sp1 transcription 
factor binding elements (SP1 CLUSTER) in addition to two smaller individual putative 
Sp1 sites (black boxes).  (B) Sp1 and DRIP-130 activate different KiSS-1 promoter-
luciferase constructs, including the 1Kb, the 150bp, and the first 100 base pairs preceding 
the start site.   
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KiSS-1 promoter, co-expression of both Sp1 and DRIP-130 resulted in a 6-8 fold increase 
in the highly metastatic melanoma cell line, WM2664 (Fig. 13B).  In an effort to determine 
the discrete region modulating the Sp1 and DRIP-130 response, luciferase assays using 
serial truncations of the KiSS-1 promoter sequence were performed.  Nearly the same fold 
increase in KiSS-1 transactivation could be observed using the 1000-, 150- and the 100-
base pair sequence of the KiSS-1 promoter, suggesting that the region modulating KiSS-1 
transcriptional activation was located near the 100bp start site of KiSS-1 gene (Fig. 13B).   
To examine whether the effects of Sp1 and DRIP-130 on the activation of KiSS-1 
promoter are tissue/cell specific, we further measured the transcriptional activation of 
KiSS-1 promoter by Sp1 and DRIP-130 in four different metastatic cancer cell lines, two 
melanoma (WM2664 and A375SM) and two breast cancer cell lines (T47D and MDA-
435).  As shown Figure 14C, cotransfection of Sp1 and DRIP-130 significantly activated 
the luciferase activity of the KiSS-1 promoter in two metastatic melanoma cells, WM2664 
and A375SM.  Interestingly however, only slight activation of the KiSS-1 promoter was 
observed upon overexpression of Sp1 and DRIP-130 in the two highly-metastatic breast 
cancer cell lines, T47D and MDA-435 (Fig. 14), suggesting that the transcriptional 
activation of KiSS-1 by Sp1 and DRIP-130 may be tissue-specific, being regulated by Sp1 
and DRIP-130 in the melanoma cell lines (Fig. 14).   
KiSS-1 Levels in Highly Metastatic Melanoma Correlates Directly to the Expression 
of DRIP-130 mRNA and Protein  
To determine whether a correlation existed between the expression of KiSS-1, Sp1 
and DRIP-130 in melanoma, we examined the expression levels of these genes in
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Figure 14:  DRIP-130 Transcriptional Up-regulation is Cell-Type Specific.  Luciferase 
assays in both metastatic melanoma (WM2664 and A375SM) and breast cancer cells 
(T47D and MDA-435) show a synergistic effect of Sp1 and DRIP-130 on transcriptional 
activation of the 100bp KiSS-1 promoter only in melanoma cells.   
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melanoma cell lines of different metastatic capacities (Figure 15).  Due to the lack of a 
specific and effective KiSS-1 antibody, the KiSS-1 expression level in the melanoma cell 
lines was quantitated using RT-PCR and normalized to the β-actin level within each 
sample.  Results showed that the more metastatic cell lines, A375SM and WM2664, 
showed considerably less expression of both KiSS-1 and DRIP-130, as compared with the 
lesser metastatic SB2 and MeWo cell lines (Fig. 15).  Although a slight increase in Sp1 
expression was seen in the SB2 line, Sp1 expression remained relatively constant in 
different cell types.  Immunoblot analysis of actin expression was analyzed and used as a 
loading control.  To determine whether reduced expression of DRIP-130 in melanoma was 
responsible in part for decreased KiSS-1 levels found in the more metastatic WM2664 and 
A375SM melanoma cell lines, DRIP-130 was singly transfected into these cells, which 
were then lysed and analyzed for KiSS-1 expression using RT-PCR.  Since no significant 
increase in KiSS-1 mRNA levels was seen (results not shown), cells were then co-
transfected with both Sp1 and DRIP-130 after which KiSS-1 mRNA levels were examined.  
Results demonstrated that co-transfection of DRIP-130 and Sp1 induced KiSS-1 expression 
levels in both melanoma cell lines (Fig. 16, middle, co-transfected) as compared to the 
untransfected cells (Fig. 16, top).  Singly over-expression of Sp1 will not result in such an 
increase of KiSS-1 expression in either cell type.  Together with our transcriptional 
activation assays using KiSS-1 luciferase promoters, our data suggests that over-expression 
of both Sp1 and DRIP-130 is required for this up-regulation of KiSS-1 in metastatic 
melanoma cell lines.   
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Figure 15:  Reduced Expression of DRIP-130 in Highly Metastatic Melanoma Cells 
Correlates with the Expression Level of KiSS-1.  Western blot analysis of DRIP-130 
and Sp1 was compared to KiSS-1 RT-PCR analysis in both non-metastatic (MeWo and 
SB2) and metastatic (WM2664 and A375SM) melanoma cells.  Reduced DRIP-130 
expression seen in metastatic melanoma correlated directly with reduced mRNA levels of 
KiSS-1.  Sp1 levels remained relatively unchanged between cell lines examined.  Actin 
controls for Western analysis and β-actin controls for RT-PCR analysis (data not shown) 
were carried out to ensure equal protein loading of samples.   
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Figure 16:  Co-Transfection of DRIP-130 and Sp1 in Highly Metastatic Melanoma 
Up-regulates KiSS-1 Expression.  Co-transfection of WM-2664 and A375SM cells with 
DRIP-130 and Sp1 resulted in higher KiSS-1 mRNA expression (middle) in RT-PCR 
analysis as compared with the untransfected melanoma lines (top). 
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Determination of the KiSS-1 Promoter Region Responsive to Transcriptional Up-
regulation by DRIP-130 and Sp1 
To demonstrate the importance of the first 100 bases of the KiSS-1 promoter in 
mediating the effects of Sp1 and DRIP-130, we measured the levels of luciferase induction 
by constructs driven by just the first 100bp of the KiSS-1 promoter or by a promoter 
construct with targeted deletion of this first 100bp.  Results showed that the 100bp region 
just proximal to the KiSS-1 transcriptional start site was sufficient for the transcriptional 
activation of the KiSS-1 promoter mediated by DRIP-130 and Sp1 (Fig. 17).  Deletion of 
the 100bp region of the KiSS-1 promoter resulted in the loss of response to Sp1 and DRIP-
130 transcriptional regulation (Fig. 17, last three columns).   Additionally, these results 
suggest that while many putative Sp1 sites are located throughout the full-length human 
KiSS-1 promoter, the transcriptional effects of DRIP-130 and Sp1 expression may be 
restricted to just that sequence within the first hundred bases of the promoter.   
To further support the significance of Sp1 binding elements localized within the 
100bp region proximal to the KiSS-1 start site, EMSA was performed to determine whether 
these sites were capable of binding the Sp1 transcription factor.  Within the first hundred 
base pairs of the human KiSS-1 promoter sequence, a single GC-rich region spanning +93 
to +58 and consisting of approximately ten overlapping putative Sp1 elements stood out as 
the likely candidate for modulating DRIP-130 and Sp1 up-regulation of KiSS-1 gene as 
identified by TESS computer analysis.  Thus, this region was initially tested for Sp1 
binding.  WM2664 cells, which were transfected to overexpress DRIP-130 and Sp1, were 
lysed and incubated with a radiolabeled probe spanning fifty bases of the promoter
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Figure 17:  Sp1 Cluster in the First 100bp of KiSS-1 Promoter is Essential for 
Modulating DRIP-130/Sp1-Mediated Activity.  Targeted deletion of 100bp region of 
KiSS-1 promoter containing Sp1 cluster losses its response to activation by Sp1 and DRIP-
130,  Expression of a 900bp KiSS-1 promoter-driven luciferase construct lacking the first 
100bp (∆100bp KiSS-1) eliminates DRIP-130/Sp1 modulation, when expressed in 
malignant melanoma WM2664.    
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sequence including the candidate GC-rich region.   Upon electrophoresis of the proteins 
and phosphor screen visualization, the patterns of bands revealed that Sp1 formed a DNA-
protein complex in the EMSA assay (Fig. 18, lane 2).  Incubation of an unlabeled probe 
competed for protein binding, resulting in a reduction of DNA-protein complex and band 
intensity (Fig. 18, lane 3).  Only the Sp1-specific antibody was capable of super shifting the 
DNA-protein complex (Fig. 18, lane 5) while the control anti-IgG antibody has no effect 
(Fig. 18, lane 4), suggesting Sp1 protein interaction with the labeled sequence of the KiSS-
1 promoter.  The negative control in which labeled probe is seen in the absence of nuclear 
extract is shown in Figure 18, lane 1.  EMSA results using Sp1/DRIP-130 co-transfected 
A375SM cells showed similar results (data not shown), suggesting that direct interaction of 
Sp1 occurs within this short 50bp region, specifically the 34 bases identified through 
computational analysis to consist entirely of overlapping Sp1 sites.   
DRIP-130 and Sp1 Complex Co-Precipitate with Chromatin at GC-rich 34-bp Region 
of KiSS-1 Promoter in Melanoma  
As DRIP-130 is known to be a component of the larger CRSP co-activator complex 
required for Sp1 transcriptional activation, the ability of DRIP-130 to interact with the 
chromatin bound 100-bp fragment of the KiSS-1 promoter was examined.  Chromatin 
immunoprecipitation (ChIP) analysis in which sheared DNA isolated from DRIP-130/Sp1 
co-transfected WM2664 melanoma cells was immunoprecipitated overnight using 
antibodies specific to DRIP-130, Sp1, and IgG.  Precipitates were then washed.  Primers, 
which were designed to overlap the Sp1 rich cluster between +1 and +150, were used to 
amplify the fragment of the immunoprecipitated chromatin (Fig. 19A).  Results showed 
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Figure 18:  EMSA Reveals Sp1 Interaction with the Sp1 Cluster.  This DNA-protein 
interaction is specific for Sp1 (lane 5), as anti-IgG was incapable of supershifting the bands 
(lane 4).  Additionally, competition for protein binding was shown using unlabeled probe 
(100X CC; lane 3).  Probe controls in the presence (lane 2) and absence (lane 1) are also 
shown.  (C)  Primers spanning the first 156bp of the KiSS-1 promoter were designed for 
chromatin immunoprecipitation analysis (CHiP) to determine if Sp1 and/or DRIP-130 
antibodies could precipitate the Sp1 cluster-containing portion of the chromatin-bound 
KiSS-1 promoter.   
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Figure 19:  ChIP Analysis Reveals Specific Interactions of Sp1 and DRIP-130 with 
the KiSS-1 Promoter.  ChIP demonstrated specific binding of Sp1 and DRIP-130 proteins 
(lanes 4 and 5, respectively) to the chromatin-bound KiSS-1 promoter in WM2664 cells.  
Precipitation using an IgG-specific antibody was used as a negative control (lane 3), 
whereas, the positive control for the PCR reaction using a KiSS-1 promoter expressing 
construct is seen in lane 1.  A portion of the chromatin-bound promoter prior to antibody 
incubation was also used as a control for the PCR reaction (lane 2). 
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that the antibody to Sp1 was able to immunoprecipitate the first 150-bp of the chromatin-
bound KiSS-1 promoter (Fig. 19B, lane 4).  However, the antibody to IgG, used as a 
negative control, did not precipitate this region of the KiSS-1 promoter and thus did not 
form PCR product (Fig. 19B, lane 3).  Controls included the PCR products using both the 
non-immunoprecipitated input (lane 2) and a vector containing the full-length KiSS-1 
promoter sequence (lane 1).  Furthermore, the antibody to DRIP-130 immunoprecipitated 
this region of the KiSS-1 promoter (Fig. 19B, lane 5).  Previous incubation of DRIP-130 
specific antibody in EMSA assays showed no conclusive DNA-protein interaction (data not 
shown), however, such seemingly inconsistent findings may likely result from even very 
small differences in the antibody or protein binding conditions in EMSA and CHiP assays.  
Generally, however, CHiP assays are considered the most sensitive and CHiP assays using 
A375SM cells were consistent with the results from WM2664 cell line.  From our CHiP 
assays, we conclude that DRIP-130 exist in a protein complex that binds to the Sp1 cluster 
between +93 and +58 in the chromatin-bound form. 
Co-Transfection of Metastatic Melanoma Cell Lines with DRIP-130 and Sp1 Results 
in Reduced Migratory and Invasive Properties 
KiSS-1 is known to inhibit migration and invasion when overexpressed in NIH3T3 
cells and other cells (Stafford et al., 2002; Lee and Welch, 1997a).  Considering that co-
transfection of both DRIP-130 and Sp1 resulted in an increase of KiSS-1 expression as 
evaluated by RT-PCR (Fig. 15), functional assays measuring the degree of invasive and 
migratory behavior of melanoma cells were used to determine whether re-introduction of 
DRIP-130 and Sp1 in highly metastatic melanoma was sufficient to induce the metastatic 
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inhibition seen with KiSS-1 overexpression.  Wound-healing assays using WM2664 cells 
transfected with vector-only (Fig. 20A), Sp1 (Fig. 20C), DRIP-130 (Fig. 20D), and Sp1 and 
DRIP-130 (Fig. 20E), were used to determine migratory ability of cells upon treatment.  
Scratches across each well were made with a pipette tip 36 hours following the initial 
transfection when cells grew confluent.  After 24 hours incubation, cell migration within 
each well was compared to a KiSS-1 transfected positive control (Fig. 20B).  A typical 
freshly made wound upon washing once with PBS before incubation was shown in Fig. 
20F).  Results show that only DRIP-130/Sp1-cotransfected (Fig. 20E) and KiSS-1-
transfected (Fig. 4B) melanoma cells show any significant inhibition to cell migration after 
24 hrs upon injury.  DRIP-130-transfected (Fig. 20D) and vector-transfected cells (Fig. 
20A) showed a good similar amount of wound healing, whereas, Sp1-transfected cells 
seemed to show slightly greater migratory capacity (Fig. 20C).  In addition, Boyden 
Chamber invasion assays using similarly transfected cells revealed that cell over-
expressing DRIP-130 and Sp1 modulated anti-invasive behavior comparable to KiSS-1 
transfected cells (Fig. 21G).  These functional assays suggest that re-introducing DRIP-130 
and Sp1 into highly metastatic melanoma cells will result in reduced invasive and 
migratory behavior similar to the anti-metastatic property produced upon KiSS-1 over-
expression in the melanoma cells.  
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Figure 20:  Co-Transfection of DRIP-130 and Sp1 Induces Anti-Migratory 
Characteristics in Metastatic Melanoma.  (A-F)  Wound healing assays were used to 
determine if over-expression of Sp1 and DRIP-130 in melanoma cells would mimic the 
anti-migratory properties seen in KiSS-1 transfected cells.  WM2664 cells were singly 
transfected with Sp1 or DRIP-130 (C and D, respectively) and compared to the vector-
transfected negative control with little or no significant difference (A).  Likewise, 
melanoma was co-transfected with Sp1 and DRIP-130 (E) and showed significant 
inhibition of cell migration as compared to the negative control (A).  Wound healing 
assays were also done on KiSS-1 expressing cells as a positive control (B).  A typical 
wound seen after washing with PBS before overnight incubation (F).   
 
 63
0
100
200
300
400
500
600
Ve
cto
r 
Ki
SS
-1
 
Sp
1 
DR
IP
-1
30
 
DR
IP
-1
30
   
   
    
   
    
   
 
+ 
 S
p1
N
um
be
r M
ig
ra
te
d 
C
el
ls
N
um
be
r M
ig
ra
te
d 
C
el
ls
 
 
Figure 21:  Co-Transfection of DRIP-130 and Sp1 Induces Anti-Invasive 
Characteristics in Metastatic Melanoma.  Results from Boyden chamber migration 
assays demonstrate that co-transfection of Sp1 and DRIP-130 leads to significant 
migratory inhibition compared to single transfections, similar to the inhibitory effect of 
KiSS-1 overexpression in the cells.   
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Discussion 
Loss of KiSS-1 expression has been repeatedly found in the progression of multiple 
forms of cancer metastasis and thus, the degree to which it is lost has become a fairly 
accurate indicator of the severity of tumor metastasis (Lee and Welch, 1997b; Sanchez-
Carbayo et al., 2003; Masui et al., 2004; Ikeguchi et al., 2004.; Kotani et al., 2001).  Re-
introduced expression of KiSS-1 in highly metastatic cells which have progressively lost 
KiSS-1, has been shown to inhibit migration and invasion of cells and cancer metastasis 
(Lee and Welch, 1997b; Muir et al., 2001; Ohtaki et al., 2001; Kotani et al., 2001; Stafford 
et al., 2002).  Considering the importance of KiSS-1 expression in gauging metastasis, an 
understanding of the transcriptional regulation of KiSS-1 and the mechanism whereby it is 
lost during the progression of cancer is essential.  Here we demonstrate that KiSS-1 
transactivation is controlled not only by the transcription factor, AP-2α, as previously 
published in breast cancer cells (Mitchell et al., 2006), but also by the Sp1 co-activator 
complex DRIP-130.  Specifically, loss of DRIP-130, one of 15 subunits which collectively 
forms the CRSP co-activator (Taatjes and Tjian, 2004), leads to the loss of KiSS-1 
transcriptional activation in metastatic melanoma cells.  
 DRIP-130 was originally identified along with the other subunits of CRSP as being 
essential for Sp1-mediate gene transcription (Ryu et al., 1999).  In addition, other labs have 
found a correlation between loss of DRIP-130 and loss of KiSS-1 expression, although the 
exact mechanism behind this correlation was never made (Goldberg et al., 2003).  The 
genomic region encoding DRIP-130, the short arm of human chromosome 6 (6q16.3-q23), 
is commonly lost as a result of the progression of melanoma.  In addition, this same region 
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of chromosome 6 encodes AP-2α, the expression of which has previously been shown to 
regulate transcription of KiSS-1 in breast cancer, suggesting that loss of this region of the 
genome is a key milestone in the loss of KiSS-1 expression and heightened metastasis 
(Goldberg et al., 2003; Mitchell et al., 2006).   Although the GC-rich KiSS-1 promoter 
contains multiple Sp1 sites, serial truncations of the KiSS-1 regulatory region revealed that 
the site responsible for modulating DRIP-130/Sp1 transcriptional regulation was localized 
to the first 100-bp (Fig. 13).  This region contained multiple overlapping Sp1 sites, and its 
deletion led to a total lack of transactivation upon co-transfection with DRIP-130 and Sp1 
(Fig. 17).  Later, the ability of both a Sp1-specific antibody to supershift the discrete 34-bp 
region just proximal the KiSS-1 transcription start site in EMSA assays indicated that this 
element may modulate Sp1 transactivation through action of DRIP-130.  Chromatin 
immunoprecipitation (CHiP) using this region of the promoter also demonstrated that Sp1 
and DRIP-130 were capable of forming a complex with the promoter region (Fig. 19A and 
19B).  Although targeted mutations of the overlapping Sp1 sites were attempted, due to the 
high GC-content, we found that generation of 100-bp constructs bearing such mutations to 
the KiSS-1 promoter was not feasible, therefore we are unable to determine which Sp1 
elements, or whether all elements in the 34bp Sp1 cluster are essential for Sp1-mediated 
transcriptional control.   
 The data presented here, as well as data from previous publications, indicates the 
overall importance of the genetic material on the small arm of chromosome 6 (6q16.3-q23) 
in maintaining KiSS-1 expression (Goldberg et al., 2003; Mitchell et al., 2006).  
Additionally, it suggests a possible mechanism for loss of KiSS-1 during tumor metastatic 
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progression, by which gross chromosomal loss of the genetic material on chromosome 
6q16.3-q23 encoding both AP-2α and DRIP-130 in melanoma, leads to reduced KiSS-1 
expression (Fig. 22).  In normal cells, DRIP-130 is expressed properly and interacts with 
other proteins in the CRSP complex that helps form the larger Mediator complex which 
binds TFIID to regulate Sp1-mediated transcriptional regulation (Fig. 22A).  Mutation or 
loss of the genomic portion of chromosome 6q16.3-q23 encoding DRIP-130 results in loss 
of KiSS-1 expression through failure of proper CRSP and Mediator complex formation 
(Fig. 22B), resulting in loss of metastatic inhibition seen in metastatic melanoma lacking 
KiSS-1 expression. 
 The transcription factor Sp1 regulates multiple genes expressed in both normal and 
tumorigenic tissues (Lania et al., 1997; Suske, 1999; Black et al., 2001; Safe and 
Abdelrahim, 2005).  Genes involved in cell cycle progression, cell growth and 
differentiation, apoptosis, and capillary growth have all been shown to contain GC-rich Sp1 
elements that regulate their expression (Ryuto et al., 1996; Finkenzeller et al., 1997; Ji et 
al., 1997; Dong et al., 1999).  Recent studies suggest that Sp1 expression may also be a 
determining factor in tumor metastatic progression; such studies indicate that higher Sp1 
levels correlate directly to severity of gastric, colonic, breast, thyroid and pancreatic 
cancers through their transactivation of vascular endothelial growth factor, insulin-like 
growth factor I, sodium-iodide symporter, and E-cadherin (Wang et al, 2003; Yao et al., 
2004; Jiang et al., 2004; Wang et al., 2005; Shi et al., 2001; Abdelrahim et al., 2005; Zhu et 
al., 2002; Liu et al., 2005).  Another explanation for increased Sp1 in such cases, however, 
is that the normal ratio of Sp1 expression is altered such as in the overexpression of 
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Figure 22:  Schematic model of DRIP-130/Sp1-Mediated KiSS-1 transcriptional 
regulation.  In normal skin cells in which chromosome 6 is intact (A), DRIP-130 is 
expressed properly and interact with other protein subunits in the CRSP complex that helps 
form the larger Mediator complex which binds TFIID to regulate Sp1-mediated 
transcriptional regulation of KiSS-1 gene.  (B) Mutation or loss of the genomic portion of 
chromosome 6q16.3-q23 encoding DRIP-130 results in loss of KiSS-1 expression through 
failure of proper CRSP and Mediator complex formation, resulting in loss of metastatic 
inhibition seen in metastatic melanoma lacking KiSS-1 expression. 
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thrombin receptor (PAR-1) in highly metastatic melanoma (Tellez et al., 2003).  Tellez et 
al., explains how an irregular ratio of AP-2α/Sp1 in which AP-2 is lost leads to the 
heightened expression of PAR-1.  Considering that Sp1 levels remain relatively constant in 
both normal and metastatic melanoma (Fig. 15), a similar mechanism by which the DRIP-
130/Sp1 ratio is reduced may likewise account for the loss of key genes in tumor metastasis 
suppression and increased tumor metastasis.   Such an increase in metastasis may occur not 
only through loss of DRIP-130 co-activation of KiSS-1, but also through increased Sp1 
modulated activation of pro-metastatic genes. 
 Although our lab previously found that AP-2α is a key regulator of KiSS-1 in 
metastatic breast cancer cells, our data now indicates the presence of a second gene, DRIP-
130, that localizes to the same chromosomal region as AP-2α, and similarly regulates the 
transactivation of the KiSS-1 promoter (Mitchell et al., 2006).  Additionally, our data 
supported previous studies suggesting a correlation between loss of KiSS-1 expression and 
loss of DRIP-130 in metastatic melanoma cells and we have localized the responsive region 
of the promoter to within 34-bp of KiSS-1 promoter.  Considering the growing clinical 
importance of KiSS-1 as an effective suppressor of metastasis, our studies suggest a 
mechanism for its regulation in normal tissues and offer a likely mechanism for its loss 
during progression of cancer metastasis. 
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CHAPTER V 
INTRODUCTION TO THE FUNCTION OF SMALL GTPASES IN THE LENS 
 
Introduction to Small Molecule Rho GTPases 
Small molecule GTPases comprise nearly 50 different families of proteins, all of 
which function as molecular switches by cycling between an inactive GDP-bound state and 
an active GTP-bound state capable of signaling downstream effectors.  The ratio of GTP to 
GDP within the cell determines the activity of these small molecule GTPases, as do the 
regulators which govern their action.  Three major types of GTPase-binding proteins are 
known, guanine nucleotide exchange factors which promote the exchange of GDP for 
GTP, GTPase activating proteins which enhance the intrinsic GTPase activity of the 
proteins leading to their inactivation, and guanine nucleotide dissociation inhibitors which 
inhibit GTPase activity and also prevent the exchange of GDP for GTP.  Of the many 
known small molecule GTPases, the Rho family of proteins is one of the most heavily 
studied.  The Rho family consists of Rho (RhoA, RhoB, and RhoC), as well as Rac (Rac1, 
Rac2 and Rac3), Cdc42, TC10, TCL, Wrch1, Chp/Wrch2, RhoG, RhoH/TTF, and Rnd 
(Rnd1, Rnd2, and Rnd3/RhoE) of which the effects of Rho, Rac and Cdc42 have been 
characterized most extensively. 
The functions of RhoA, Rac1 and Cdc42 were originally determined when their 
expression was found to influence the formation of F-actin structures in Swiss3t3 
fibroblasts.  Upon LPA induction, the fibroblasts formed actin stress fibers and focal 
adhesions, which could be prevented by the addition of Clostridium botulinum C3 
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exoenzyme, an enzyme which ADP-ribosylates asparagine-41 inactivating Rho GTPase 
and causing depolymerization of the actin cytoskeleton.  Since then, multiple stimuli have 
been found to induce Rho family activation.  Growth factors, including platelet-derived 
growth factor (PDGF), epidermal growth factor (EGF) and insulin induce Rac1-mediated 
membrane ruffling, cell-cell adhesions and actin polymerization (Kaibuchi et al., 1999; 
Ridley and Hall, 1992), whereas bradykinin induces microspike or filopodia formation via 
Cdc42 activation (Ridley and Hall, 1992).  In addition to the cytoskeletal rearrangements 
modulated by the Rho family, these proteins have also been found to regulate multiple 
biochemical processes upon stimulation of upstream membrane receptors, including G1-
cell cycle progression, membrane trafficking, nuclear factor NF-κB (Perona et al., 1997) 
and serum response factor transcription factors (Hill et al., 1995), NADPH oxidase 
complex (Abo et al., 1991), the c-jun N-terminal kinase (JNK) (Minden et al., 1995) and 
p38 mitogen activated protein kinase pathways (Coso et al., 1995).  The deep involvement 
of the Rho family of GTPases in nearly every major pathway underscores the importance 
of these proteins as key signaling intermediaries. 
Rho Family in the Lens 
Small GTPases were originally implicated in the processes involved in lens cell 
development and proliferation nearly a decade ago when their presence was found to be 
highly enriched in insoluble lens fractions using GTP overlay assay (Rao et al., 1997b).   A 
combination of two-dimensional electrophoresis and GTP overlay identified over 25 small 
molecule GTPases between 20-30 kDa, including both Rho and Rac.  Additionally, 
incubation of lens fractions with C3-exoenzyme confirmed the presence of Rho in lens 
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lysates by their ability to become ADP-ribosylated in vitro (Rao et al., 1997b).  The 
abundance of Rho family proteins in the lens suggested they may play important roles in 
actin rearrangement, integrin signaling, cellular differentiation, or other cellular processes 
in which Rho GTPases are known to be intricately involved.  No direct influence of the 
Rho family on lenticular differentiation, function and structure, however, was seen until 
just a decade ago when studies showed that treatment of lenses with lovastatin, a 
cholesterol-reducing agent, was also was found to prevent iso-prenylation of Rho proteins, 
effectively blocking Rho recruitment to the membrane (Rao et al., 1997a).  Lovastatin was 
found to induce aberrant cell proliferation and decreased lens transparency leading to 
cataract formation via its ability to inhibit Rho signaling.  Lovastatin treatment of both 
human and rabbit lenses resulted in overall deterioration of the lenticular epithelium, 
increased vacuole development in the cortex, and distortion of elongating lens fiber cells 
(Rao et al., 1997a).  Since then, further studies have illustrated the importance of 
expression of Rho proteins during eye development and maintenance.  As Rho GTPases 
have been found to be expressed in lens tissue, it is likely that their activity may influence 
lens cell differentiation and cytoskeletal morphology, and possibly lens transparency as 
well.   
Although once thought to be ubiquitously and uniformly expressed, recent evidence 
suggests that the Rho family of GTPases are commonly differentially expressed and that 
such unique patterns of expression, both spatial and temporal, are necessary for the 
physiological activities of the Rho family proteins.  Such differential distribution has 
already been found in the rat hippocampus, cerebellum and neocortex (O'kane et al., 2003; 
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Olenik et al., 1999) and implies that these proteins have unique effects and are required 
during specific periods of development.  The differential expression patterns of the Rho 
proteins in the eye may indicate that they are responsible for different aspects of lens cell 
function and maintenance.  Differential expression of the Rho family of GTPases has been 
found in the chick retina in which these proteins were expressed differently during 
different developmental stages (Santos-Bredariol et al., 2002).  Additionally, RhoB was 
found to be almost exclusively in the lens after 11.5E day and was only strongly expressed 
between postnatal days 7-18 in the retina suggesting it is required only during lens fiber 
elongation and in the development of the retina (Maddala et al., 2001a). 
Upstream Activators of Rho Family GTPases:  Growth Factor Mediated Cell 
Signaling through the Rho family 
The Rho family of GTPases primarily work to transduce the effects of extracellular 
signals to downstream modulators of the actin cytoskeleton through membrane receptors.  
Growth factor receptors commonly mediate signals to Rho, Rac and Cdc42 by activating 
guanine exchange factors, or alternatively, by inhibiting guanine activator proteins, 
therefore activating the GTPase signaling pathway. Rho was first found to be antagonized 
upon treatment with lysophosphatidic acid (LPA), which induced the formation of the actin 
stress fibers in Swiss3T3 cells.  This response results from LPA signaling via multiple G-
protein coupled receptors (Ridley and Hall, 1992; Goetzl and An, 1998).  
Lysophospholipid, is a bioactive lipid growth factor which regulates multiple processes 
involved in cytoskeletal reorganization, including proliferation, adhesion and migration. 
Previous immunohistochemistry in the lens revealed that both LPA and sphinogosine-1 
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phosphate receptors were expressed strongly in cortical actin stress fibers as well as in 
focal contacts of serum-starved lens epithelial cells as active Rho GTPase levels were 
increased (Okamoto et al., 2000).  This effect of LPA on cytoskeletal organization in the 
lens appeared to be similar to the effects of b-FGF, transforming growth factor-β (TGF-β), 
and platelet-derived growth factor (PDGF), suggesting a potential role for this lipid agonist 
in lens epithelial cell migration, proliferation, and cell survival (Maddala et al., 2003).  
Both LPA and thrombin are known to signal through Rho GTPase mediated pathways in 
order to effect cytoskeletal reorganization  (Hall, 1998; Van Aelst and D'Souza-Schorey, 
1997; Essler et al., 1998; Jalink et al., 1994).  Active thrombin receptor has also been 
identified and characterized in the human lens (James et al., 2005) and considering that 
thrombin induces rapid geranylgeranylation of RhoA, leading to its activation in 
endothelial cells, it may prove equally as important in lens tissues (Ohkawara et al., 2005). 
Fibroblast growth factor (FGF) is solely responsible for differentiation of lens 
epithelial cells into lens fiber cells (de Iongh et al., 1997) and is constantly expressed 
throughout normal eye development and maintenance.  Although TGF-β and FGF have 
been shown to have opposing effects on lens cell proliferation in vitro, as TGF  decreases 
whereas FGF increase cell number (Nishi et al., 1996; Ueda et al., 2000), FGF has also 
been found to aggravate the effect of TGF-β possibly by inducing cell proliferation when 
concomitantly repressing TGF-β-stimulated cell death (Cerra et al., 2003) .  Additionally, 
FGF-2 expression is required for increased cell proliferation in injured lens cells in vitro, 
suggesting it has an additional role in cytoskeletal rearrangement during wound healing 
(Tanaka et al., 2004). 
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Transforming Growth Factor-β Signaling via Rho GTPases 
TGF-β has been implicated in multiple human diseases  (Blobe et al., 2000), 
including lenticular anomalies resembling those characteristic of  posterior capsule 
opacification and subcapsular cataract development  (Liu et al., 1994; Hales et al., 1995; 
Srinivasan et al., 1998; Hales et al., 1999; de Iongh et al., 2001).  Overexpression of TGF-β 
in rat model systems has shown that TGF-β is responsible for the epithelial-mesenchymal 
transition that is characteristic of cataratogenesis and precedes expression of collagen type 
I, alpha-smooth muscle actin, fibronectin, and tanascin, hallmarks of cataractous lens tissue 
(Cerra et al., 2003; Marcantonio and Reddan, 2004).  TGF is strongly expressed in lens 
epithelium, and is expressed in a latent form in the ocular media (Jampel et al., 1990; 
Ochiai and Ochiai, 2002).  Although the exact mechanism of TGF-β induced Rho 
activation is unknown, the cytoskeletal rearrangements modulated upon TGF-β treatment 
are known to modify Rho family GTPase activation (Masszi et al., 2003).  Rho may 
mediates TGF-β induced epithelial-mesenchymal transition in part by stimulating the 
cytoskeletal rearrangement through activation of myosin light chain or inhibition of 
myosin light chain phosphatase via the Rho kinase, in addition to activation of serum 
response factor-mediated transactivation of the alpha smooth muscle promoter (Masszi et 
al., 2003). 
Cataract removal commonly induces a wound healing response marked by 
opacification of the remaining lens capsule (Tanaka et al., 2004).  This response often 
stimulates expression of extracellular matrix proteins and integrins, as well as structural 
elements.  TGF-β modulates multiple biological processes including apoptosis, cell 
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proliferation, migration and adhesion (Lee and Bae, 2002; Zhu et at., 2005). TGF-β is also 
believed to play a principle role in initiating cell signaling in response to lens injury and is 
highly expressed in the aqueous humor of the human eye (Marcantonio and Reddan, 2004).   
Thus, signaling mediated through the transforming growth factor receptor has roles both in 
the normal processes involved with lens fiber differentiation, as well as inappropriately 
during epithelial-mesenchymal transition and is similar to certain types of cataracts 
including anterior subcapsular and posterior capsular opacification, which develop after 
cataract surgery (Gordon-Thomson et al, 1998; Wormstone et al., 2002).  Posterior capsule 
opacification is known to result when cell proliferation, matrix deposition, and capsular 
wrinkling cause increased scatter of light through the lens (Marcantonio and Reddan, 
2004).  TGF-β2 has been found to influence alpha5-β1 integrin distribution in vitro (Liu et 
al., 1994; Lee and Joo, 1999; Wormstone, 2002). And, in vivo experiments in which 
exogenous TGF-β is added show  a marked increase in the incidence of cataractous 
changes (Hales et al., 1999).  TGF-induced cataract formation also results from stimulation 
of the Smad signaling pathways (Saika et al., 2001; Wormstone et al., 2004).  Smads 
transduce signals from TGF-β receptors on the cell surface to the nucleus where they bind 
as a complex to certain promoter regions where they regulate transcriptional activity (Piek 
et al., 1999; Massague and Wotton, 2000).  Activation of the TGF-Smad pathway leads to 
increased apoptosis and decreased cell proliferation (Chen et al., 2001).  Using breast 
epithelial cells as a model system, Rho signaling has been shown to be essential in 
mediating TGF-β induced growth inhibition (Kamaraju and Roberts, 2005).  Activation of 
Rho kinase leads to phosphorylation of serine residues in the linker regions of Smad2 and 
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Smad3, leading to Smad activation, resulting in down-regulation of c-myc and up-
regulation of p21waf1 causing growth suppression and loss of cell proliferation (Kamaraju 
and Roberts, 2005).   Contrarily, Cdc42 is activated by Smad7, a negative regulator of the 
TGF-β-Smad signaling pathway in breast carcinoma and prostate epithelial cells which 
leads to actin cytoskeletal rearrangement, inhibition of Smad2 and Smad3 phosphorylation 
and ubiquitination of the cognate TGF-β receptor (Edlund et al., 2003; Kavsak et al., 2000; 
Ebisawa et al., 2001).  As RhoA commonly antagonizes the effects mediated by Rac1 and 
Cdc42, it is possible that whereas RhoA mediates the initial wound response in the lens via 
Smad transcriptional modulation, Smad induced Cdc42 expression may be concomitant 
with later actin filament reorganization through activation of p38 pathway (Edlund et al., 
2004).  Although TGF-β signaling is principally through the activation of Smad proteins, 
Smad-independent TGF-β signaling pathways have also been identified.  TGF-β treatment 
of rat basophilic leukemia and human prostate epithelial cells results in a rapid (within 5-
10 minutes) induction of lamellipodia formation through activation of Rho GTPases 
(Edlund et al., 2002).  This is then followed by conventional TGF-β signaling through 
phosphorylated Smads leading to formation of actin stress fibers.  
Role of Rho Family GTPases in Lens Cell Adhesion 
The lens is composed of a single epithelial layer.  Lens epithelial cells located at the 
equatorial region migrate posteriorly, bringing them into contact with the vitreous humor 
which contains factors which induce cells to terminally differentiate into fiber cells.  This 
process is continuous.  Over the course of a lifetime, the newly differentiated fiber cells 
displace older fiber cells pushing them towards the center of the lens.  The oldest of these 
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cells, the nucleus, thus represents those cell which composed the earliest embryonic lens, 
and the peripheral region, the cortex, consists of the biologically active portion of the lens.  
The lens thus consists primarily of two distinct cell types:  lens epithelial cells which are 
situated at the anterior region of the eye, and the lens fiber cells, which are found in the 
cortical and posterior regions.  Normal differentiation of the lens epithelial cells involves 
loss of cuboidal shape characteristic of epithelial cells and the adoption of a more elongate, 
ribbon-like morphology, as well as the loss of cellular organelles, including the nucleus.  
The process of elongation, coupled with the directed migration of lens cells requires cells 
to continuously make and dissolve cell-cell and cell-matrix adhesions and generate 
contractile forces.  Aberrations in these processes may lead to irregular lens shape and 
function.  As the Rho family is intricately involved in these processes, they are likely to be 
key regulators of structural signaling in the lens. 
The first step in the process of epithelial cell migration involves extension of the 
lamellipodia or filopodium at the leading edge primarily by the action of Rac1 and Cdc42.  
Further, extension is regulated by G-proteins, as well as actin-capping proteins (Etienne-
Manneville and Hall, 2002).  Following the initial elongation, integrins bind protein in the 
extracellular matrix (ECM) to form weak attachments, which are quickly reinforced by the 
formation of focal adhesions which incorporate both signaling and scaffolding proteins.  
Nuclei and cytoplasmic migration is mediated by myosin dependent contraction of the 
actin cytoskeleton.  Disassembly of focal contacts at the trailing edge of the cell then 
releases the cell from the ECM and allows the trailing end to be retracted into the body of 
the cell.  Adhesion and migration requires a high degree of coordination since these two 
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processes may be seen to act contrary to one another, in that a high level of adhesion will 
inhibit migration by preventing detachments, and low adhesion may also hamper migration 
by not providing sufficient traction for movement.  Epithelial cell migration differs from 
migration of fibroblasts in that rather than migrating individually, cells migrate as sheets, 
thus maintaining the barrier quality of epithelium.  Additionally, epithelial cells do not 
form focal adhesions although they express those proteins which constitute focal contacts 
and are used in creating cell-ECM connections.  The contractile force that propels the 
epithelial sheet is provided by actin fibrils found perpendicular to the migrating cells 
(Fenteany et al., 2000).  As the connection with the ECM provides the migratory force, 
abnormal in the composition of the ECM can interfere with such interactions and lead to 
defects in migration.  In the lens, the lens capsule provides the ECM and is composed of 
fibronectin, collagen IV, and laminin (Cammarata et al., 1986).   
Integrins modulate signals from the ECM to the cell’s interior which may affect 
survival, proliferation, and cell differentiation.  Signals may also be mediated outwardly 
from within the cell and thus may affect migration of the cell by modulation of the 
extracellular matrix.  Modulation of the actin cytoskeleton is primarily resultant of Rho 
GTPase signaling, as its downstream effects Rho kinase and LIM kinase alter actin-based 
cytoskeletal structures through modulation of myosin light chain and myosin light chain 
phosphatase activation. While the initial clustering of integrins into focal adhesions is Rho 
independent, cell contraction through activation of Rho proteins leads to further 
aggregation of integrins and the formation of larger focal adhesions (Machesky and Hall, 
1997; Chrzanowska-Wodnicka and Burridge, 1996; Clark et al., 1998).  In the lens, 
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supplementation of cultured human lens epithelial cells with growth factors including 
EGF, b-FGF, PDGF, LPA and TGF-β results leads nearly immediate increases in Rho 
GTPase activation which were maintained for nearly an hour post-treatment (Maddala et 
al., 2003).  Whereas b-FGF, PDGF, and TGF-β induced marked increase in actin-based 
cytoskeletal reorganization, addition of EGF, which like the other growth factors was 
found to activate both Rho and Rac, elicited weak stress fiber formation but significant 
membrane ruffling and focal adhesion formation (Maddala et al., 2003).  This response to 
growth factors present in both aqueous and vitreous humors may influence lens epithelial 
differentiation as well as proliferation and migration by mediating the formation of cell-
ECM interactions critical for lens cell survival (Menko et al., 1998; McAvoy et al., 1999; 
Maddala et al., 2003).  Treatment of cell with C3-exoenzyme and a Rho kinase inhibitor, 
Y-27632, inhibited focal adhesion formation, thus supporting the essential role of Rho and 
its downstream effectors in mediating this response (Maddalla et al., 2003).  Additionally, 
recent characterization of a transgenic mouse model in which C3-exoenzyme was 
specifically expressed in the lens under the α-crystallin promoter, which functionally 
knocks out Rho GTPase activity in the lens, reveals that lenses from these mice 
demonstrate aberrant membrane architecture and altered gene expression patterns in which 
structural proteins and cell survival proteins are deregulated along with higher incidence of 
cataract formation, confirming the critical role of GTPases play in normal lens 
proliferation, differentiation, and function (Maddala and Rao, 2005).   
However, during the formation of ASC and PCO types of cataracts, lens epithelial 
cells differentiate into myoblast or mesenchyme-like cells (Wride and Sanders, 1998; Lee 
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and Joo, 1999) which require expression of cell adhesion molecules, including integrins to 
mediate both cell-cell and cell-ECM interactions.  Multiple integrins are shown to be 
highly expressed in human cataracts including β1, β2, α2 and α5, whereas others such as 
a6, a key regulator of lens cell differentiation may be downregulated (Zhang et al., 2000; 
Lim et al., 2001).  Processes involving adhesive interactions are also capable of 
modulating actin-based cytoskeletal rearrangement which involves activation of the Rho 
family of GTPases (Clark et al., 1998).  Integrins are membrane receptors located in 
discrete regions of the cell’s surface termed ‘focal adhesions’ that link the extra cellular 
membrane to collections of intracellular cytoskeletal elements leading to the formation of 
actin stress fibers (Chrzanowska-Wodnicka and Burridge, 1996; Craig and Johnson, 1996; 
Jockusch and Rudiger, 1996).  Additionally, integrin-mediated cellular adhesion can 
induce formation of other actin structures including membrane ruffles, and microspikes 
and other physiological modifications leading to cell spreading and motility (Craig and 
Johnson, 1996; Zigmond, 1996).  
Downstream Effectors of Rho Family GTPases in the Lens 
Activation of the Rho family of GTPases has also been found to influence 
transcription activation as well as cell cycle progression through activation of its 
downstream effectors, serum response factor (SRF), the CDK kinases, and cell cycle 
inhibitor expression.  RhoA is the most heavily researched member of the Rho family of 
GTPases, and as such, its involvement in lens development and cellular differentiation is 
the most highly characterized.  Two major downstream effectors are known to modulate 
the effect of Rho activation on the cytoskeleton; these are the Rho kinases and the 
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Diaphanous forming subfamily.  Rho kinases are serine/threonine kinases that induce 
reorganization of actin filament bundles by activating myosin light chain (MLC) or 
inactivating MLC phosphatase through direct phosphorylation of these substrates.  (Govek 
et al., 2005).  Additionally, activation of Rho kinase promotes inactivation of the actin 
depolymerization factor cofilin through LIMK activation leading to accumulation of F-
actin.  (Sumi et al., 1999; Amano et al., 2001).   In addition to its affects on cofilin, MLC 
and MLC phosphatase, the expression of ROCK has also been found to be inversely 
correlated to αB-crystallin expression in lens epithelial cells (Khurana et al., 2002). 
Additionally, Rho family activation has also been shown to regulate transcriptional 
modulation as well as cell cycle progression, independently of its influence on the actin-
based cytoskeleton.  Such effects as these are carried out by the downstream effectors, 
serum response factor (SRF) and by the cyclin dependent kinases (Cdk) (Maddala et al., 
2004).  Although little is known about SRF-mediated signaling in the lens, Cdk5 is known 
to regulate cell-matrix as well as cell-cell adhesions in the lens epithelium (Negash et al. 
2002)  Cdk5 positively regulates cell adhesion and is usually found at higher expression in 
the tips of elongating lens fiber cells (Gao et al., 1997; Negash et al., 2002).  Cdk5 
substrates include c-Src, myosin heavy chain, focal adhesion kinase and p21-activated 
kinase, all of which are known to regulate different aspects of cell adhesion and migration 
(Kato and Maeda, 1999; Pato et al., 1996; Xie et al., 2003; Nikolic et al., 1998; Banerjee et 
al., 2002; Zelenka, 2004).  Cdk5, which is controlled by the activation of Rac1, enhances 
adhesion of both fibronectin and collagen IV and its ability to limit active Src recruitment 
to the leading edge of corneal epithelium  suggests a possible mechanism whereby it 
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enhances migration by decreasing focal contact stability (Negash et al., 2002; Gao et al., 
2004; Frame and Brunton, 2002; Zelenka, 2004).  Rac1 and Cdc42 directly activate the 
mitogen-activated protein kinase pathway through activation of P21-activated kinase.  Rho 
also indirectly activates the Ras signaling pathway, which in turn activates the mitogen-
activated protein kinase cascade.  Expression studies of the members of the mitogen-
activated protein kinase pathways in the lens revealed that extracellular signal-related 
kinase1 and 2 (ERK 1 and ERK2) were most strongly expressed, whereas jun-N-terminal 
kinase1 and 2 (JNK1 and JNK2) and p38 kinase were found more highly expressed in the 
lens epithelium (Li et al., 2003).   
Mutations in Rho Modulated signaling Lead to Lenticular Anomalies 
Fiber cells highly express crystallin proteins, which are partly responsible for the 
transparency and reduction of light scatter.  However, fully differentiated fiber cells are 
incapable of replacing damaged regions and have limited ability to fully repair them, thus 
fiber cells must remain dependent of the surrounding lens epithelium to protect and sustain 
transparency (Rao et al., 1994).  Multiple bacterial toxins are capable of modifying the 
activity of Rho GTPases. Clostridium difficile toxin B inactivates nearly every member of 
the Rho GTPase family (Aktories et al., 2000) whereas another toxin isolated from 
Clostridium botulinum (Aktories, 1997) exhibits more specific activity, inactivating only 
RhoA, RhoB, and RhoC.  As mentioned previously, the functional knockout of Rho in 
which  the C3 exoenzyme was integrated into the control of the crystallin promoter for eye 
specific expression, showed numerous phenotypic and histological aberrations, indicating 
the important role of the Rho family in modulate the organization of the cytoskeleton of 
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the lens (Madalla et al., 2005).   Similarly lovastatin blocks Rho signaling is through the 
inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase which 
causes loss of mevalonate, a precursor for the production of farnesyl and geranylgeranyl 
lipid groups, the binding of which is required for targeting Rho proteins to the membrane 
(Goldstein and Brown, 1990).  Mutations in or loss of mevalonate kinase has also been 
shown to induce cataractogenesis supporting the claim that proper Rho regulation is 
essential for lens maintenance (Hoffmann et al., 1986).  Additionally, lovastatin treatment 
along with inducing lens opacification also decrease lens epithelial proliferation indicating 
a loss of Rho may stimulate apoptotic pathways (Rao et al., 1997b; Coleman and Olson, 
2002). 
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CHAPTER VI 
DIFFERENTIAL EXPRESSION OF SMALL MOLECULE RHO GTPASES DURING 
MOUSE EYE DEVELOPMENT 
 
Overview 
It is well established that normal eye development requires complex morphological 
changes which are mediated through various signaling transduction pathways, including 
those modulated by the Rho family proteins which regulate cell differentiation and 
cytoskeletal changes.  Currently, no data exists detailing the expression patterns of the 
three major Rho GTPases, RhoA, Rac1 and Cdc42, in the cornea and lens, nor has it yet 
been studied in the mammalian retina.   Our results demonstrate both temporal and spatial 
differences in the expression patterns of all three GTPases in the cornea, lens and retina of 
the embryonic, neonatal and adult mouse eyes.   Immunohistochemistry was used to 
examine the expression patterns of RhoA, Rac1 and Cdc42 in the embryonic (11.5 p.c., 
14.5 p.c., and 17.5. p.c.), postnatal (one day), and adult C57BL/6 mouse eye.  To confirm 
the expression pattern of these Rho GTPases, western blot and RT-PCR analysis was also 
conducted.  Results showed differences in both spatial and temporal expression throughout 
the development of the eye and into the adult tissues.  Immunohistochemistry revealed that 
all three Rho GTPases were expressed early in eye development, but that such expression 
was modulated during development differently within different ocular tissues.  Differential 
expression was maintained in the adult expression, particularly within the lens, which was 
confirmed using both western and RT-PCR analysis. The GTPases are differentially 
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expressed in the cornea, lens and retina of mouse eye during development.  The three small 
molecule GTPases are strongly expressed in the embryonic lens, with relatively less 
expression in the cornea and retina.  In the neonatal mouse, all GTPases displayed their 
strongest expression within the retina.  In the adult mouse eye, Rac1 but not RhoA nor 
Cdc42 were expressed during lens growth and secondary fiber cell differentiation.  All 
three Rho GTPases are expressed during corneal epithelial cell differentiation, however, 
only RhoA is expressed during endothelial cell differentiation.  In contrast, all three small 
GTPases are expressed in retina. 
Introduction 
Small molecule GTPases function as “molecular switches” mediating extracellular 
signaling events to downstream intracellular effectors by cycling between GDP-bound 
inactive and GTP-bound active forms upon stimulation.  The Rho family of small molecule 
GTPases, of which RhoA, Rac1 and Cdc42 are most highly characterized, are implicated in 
numerous cellular functions including cytoskeletal actin organization (Ridley and Hall, 
1992), cell growth, cell migration  (Zipkin et al., 1997),  cell adhesion (Ridley et al., 1992), 
vesicular trafficking, and differentiation (Hall, 1998).  These different Rho family GTPases 
regulate the formation of distinct structural elements; Rho induces formation of actin stress 
fibers and cell contacts, whereas Cdc42 and Rac1 regulate filopodia formation and 
membrane ruffling, respectively (Hall, 1998).  Although once thought to be ubiquitously 
and uniformly expressed in mammalian tissues, differential expression patterns of these 
proteins have been shown in the brain (O’kane et al., 2003), as well as throughout retinal 
development in the chicken (Santos-Bredariol et al., 2002).  Differences in expression of 
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these Rho family proteins in neuronal cells has proven to be essential for proper neurite 
outgrowth, as each member prompts distinct effects on the growth of neuronal processes 
and axons, and it is possible that differential expression patterns of these proteins in other 
tissues is equally important for the growth and perpetuation of other cells and systems 
(Hall, 1998) 
The vertebrate eye develops through a complex process of morphogenesis which is 
modulated by various signaling transduction pathways and governed by different families 
of regulators.   Among these regulators are the small molecule GTPases. Using radioactive 
GTPase blot overlay assays on soluble and insoluble fractions of monkey and human 
lenses, Rao (1997) first demonstrated the presence of multiple proteins primarily within the 
insoluble membrane fractions which possessed strong GTP-binding abilities, including the 
small molecule GTPases which ranged in size between 20-30 kDa corresponding to the 
molecular weights of Rho and Rac. Blockage of Rho isoprenylation in cultured rabbit lens 
epithelial cells via lovastatin treatment inhibits Rho association with the membrane, 
resulting in the distortion of elongating epithelial cells and deterioration of the central 
epithelium due to the overall loss of focal adhesions, cell-cell adhesions, protein-
phosphotyrosine and actin stress fiber degeneration (Rao et al., 1997a; Maddala et al., 
2001b).  Additionally, transgenic mice overexpressing the C3 exoenzyme, a bacterial toxin 
which inactivates Rho GTPase, showed dramatically altered cytoskeletal organization, and 
microarray analysis of transgenic lenses demonstrated aberrant expression of over forty 
different genes, including those encoding extracellular matrix and basement membrane 
proteins (Maddala et al., 2004).  Using immunohistochemistry, the same group has 
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analyzed the developmental expression pattern of another small GTPase, RhoB, in mouse 
lens from different embryonic stages to postnatal development up to 18 days.   It was 
determined that RhoB was strongly expressed in the developing lens, specifically 
paralleling the morphogenesis of the lens fiber cells.  Such results suggest its important 
role in lens differentiation (Maddala et al., 2001b).   Considering the likely role of RhoB in 
lens differentiation, the possible roles of other small molecule GTPases, such as RhoA, 
Rac1 and Cdc42 remained to be determined. 
The retina is commonly regarded as an archetype of cellular differentiation because 
of its complex composition of highly differentiated cell types.  Four members of the Rho 
family of small molecule GTPases, RhoA, RhoB, Rac1 and Cdc42, were previously found 
to be differentially expressed in developing chicken retina, however whether such 
differential expression patterns are maintained through adulthood has yet to be determined 
(Santos-Bredariol et al., 2002).  Additionally, previous studies have shown indicated clear 
differences in RhoB expression patterns between the mouse and chick lens, but whether 
such differential patterns of expression exist for the other major small molecule GTPases, 
RhoA, Rac1 and Cdc42 is an important question that has not yet been addressed. 
         To further explore the potential functions of the small molecule GTPases in 
regulating the development of different compartments of the eye, we have examined the 
expression patterns of RhoA, Rac1 and Cdc42 throughout mouse eye development.  Our 
results are the first to reveal the expression patterns of these small molecule GTPases in 
cornea, and of the temporal differences in expression patterns of RhoA, Rac1 and Cdc42 in 
the ocular lens from embryonic stages, neonatal to adult.   In addition, our studies provide 
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comparative information on the expression patterns of RhoA, Rac1 and Cdc42 in 
developing retina as well as their expression patterns in the adult retina. Together, our 
studies provide important information regarding the functions of RhoA, Rac1 and Cdc42 in 
regulating morphogenesis of the three compartments of the eye: retina, lens and cornea. 
Expression of RhoA, Rac1 and Cdc42 in the Embryonic Mouse Eye 
By 11.5 p.c., the lens vesicle itself has formed, and the ectoderm lining it begins to 
differentiate into cornea (Fig. 23A).  Compared with the control (the rightmost panel) 
expression of RhoA and Cdc42 was clearly detected in this tissue overlaying the lens 
vesicle (the leftmost panel and the third panel from the left of Fig. 23A).  In contrast, 
expression of Rac1 was nearly undetectable (the second panel from the left of Fig. 23A).   
RhoA and Cdc42 continue to be expressed at 14.5 p.c., and by this stage of development, 
expression of Rac1 also begins to appear within the cornea (Fig. 23B).  At 17.5 p.c., when 
the cornea differentiates into three different layers: endothelial cells, stroma and epithelial 
cells, expression of RhoA and Cdc42 was found more focused in the epithelial and 
endothelial cells (the leftmost panel and the third panel from the left of Fig. 23C), whereas, 
expression of Rac1 parallels this same pattern of expression but at a level significantly 
lower that RhoA and Cdc42 (the second panel from the left of Fig. 23A).   
At 11.5 p.c., strong expression of the RhoA was detected throughout the lens 
vesicle, a pattern similar to that found with RhoB (Maddala et al., 2001a) (the most left 
panel of Fig. 23A).  Expression of Cdc42 at this same stage was lower than that of RhoA, 
while Rac1 expression was barely detectable (the third and the second panels from the left  
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Figure 23:  Expression of Rho GTPases during Embryonic Development. (A) Day 
11.5 p.c. expression of RhoA, Rac1 and Cdc42 is present throughout the mesenchyme [M] 
and in the developing neuroepithelium [NE], particularly on the outer region adjacent to 
the lens vesicle [LV].  (B)  By day 14.5 p.c., expression of the Rho family GTPases is 
elevated in the highly differentiating lens fibers [L] as well as in the inner region of the 
neuroblastic layer [NB] lining the optic cup.  Expression of Rac1 is pronounced throughout 
the differentiating lens cells, whereas, RhoA and Cdc42 expression appears concentrated 
along the cuboidal layer of the lenticular cells. (C)  Day 17.5 p.c. mouse eye shows Rho 
GTPase expression at the actively dividing layer of the lens, with moderate and diffused 
expression in the neuroblastic layer. 
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of Fig. 23A, respectively).   In contrast to Rac1 expression, which was predominantly 
found in the differentiating primary fiber cells (the second panel of Fig. 23B), both RhoA 
and Cdc42 expression at 14.5 p.c., was found in differentiating primary fiber cells as well 
as in the lens epithelium and (the leftmost panel of Fig. 23B and the third lane from the left 
of Fig. 23B, respectively).  Overall, expression of Cdc42 at 14.5 p.c. is relatively higher 
than either RhoA or Rac1 (Fig. 23B).  All three small molecule GTPases are more strongly 
expressed by 17.5 p.c., displaying heavy expression in the differentiating primary fiber 
cells and in the subcortical region (Fig. 23C). Enhanced expression of all three Rho 
GTPases was found in the primary fiber cells, and increased to a lesser extent in the lens 
epithelium.  In contrast, the expression of these small GTPases was much attenuated in the 
cortical region (Fig. 23C).  
In contrast to the predominantly postnatal expression of  RhoB, RhoA was found 
expressed at 11.5 p.c. in the lens vesicle and strongly expressed in the developing 
neuroretinal layers, the neuroblastic region (the leftmost panel of Fig. 23A) (Maddala et 
al., 2001a).  During this same stage of development, the expression level of Cdc42 in retina 
was lower than RhoA, and that of Rac1 was lower still (the third and the second panels 
from the left of Fig. 23A, respectively).   At stage 14.5 p.c., expression of RhoA was 
strongly detected in the predicted photoreceptor zone and to a less degree in the ganglion 
cell layers (the leftmost panel of Fig. 23B).  Although Rac1 and Cdc41 reveal similar 
patterns of expression, the overall level of Rac1 seems higher than those of the other small 
molecule GTPases (Fig. 23B).  As development proceeds to 17.5 p.c., expression of all 
three small molecule GTPases are detected in the photoreceptor layers (Fig. 23C).  
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Expression of RhoA, Rac1 and Cdc42 in the Neonatal Mouse Eye 
Compared to the negative control (Fig. 24D), RhoA was expressed in the 
endothelium and to a lesser degree in the epithelial cells and stroma of the neonatal mouse 
(Fig. 24A).  Similarly, expression of Cdc42 was clearly detected in both endothelial and 
epithelial cells, but hardly detectable in the stroma (Fig. 24C).  In contrast to both RhoA 
and Cdc42, strong levels of Rac1 expression were noted in the fibroblasts within the 
stroma as well as in both endothelial and epithelial cell layers of the neonatal mouse cornea 
(Fig. 24B).  In the ocular lens, strong expression levels of RhoA, Rac1 and Cdc42 were 
detected in the lens epithelial cells (Fig. 24A, 24B and 24C) of the neonatal mouse in 
comparison to the negative control (Fig. 24D).  In contrast, their expression levels in the 
fiber cells were substantially decreased (Fig. 24A, 24B and 24C).  
Compared with the negative control (Fig. 24D), a strong expression level of RhoA 
was detected in the photoreceptors, the horizontal/amacrine/Muller’s cells, as well as some 
of ganglion cells of the neonatal mouse retina (Fig. 24A).  In most of the ganglion cells, 
inner and outer plexiform layers, a reduced level of RhoA was detected (Fig. 24A).   
Expression of Rac1 and Cdc42 followed a similar pattern of RhoA but the expression 
levels were decreased in the retina of neonatal mouse eye (Fig. 24B and 24C).  
Expression of RhoA, Rac1 and Cdc42 in the Adult Mouse Eye   
Contrasting the expression patterns of RhoA and Cdc42 in the cornea of the adult 
mouse eye, immunocytochemistry revealed that both RhoA and Cdc42 were absent in the 
ocular lens, neither in the epithelial cells nor in the fiber cells (Fig. 25; leftmost and 
rightmost panels).   Rac1 expression, however, was found throughout the lens, exhibiting a 
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Figure 24:  Expression of Rho GTPases in Neonatal Mouse Eye.  (A)  RhoA was 
expressed diffusely throughout the anuclear regions of the retina at day1.  Corneal 
expression of RhoA was elevated throughout the tissue, with enhanced staining at the 
endothelium.  RhoA staining in the lens fibers [LF], however, higher expression was seen 
in the lens epithelial cells [LEC] and lens capsule [LC].  (B)  Expression of Rac1 was only 
slightly detectable in the retina, but more intense staining was seen in the corneal 
endothelium as well as in the LF, particularly concentrated in the LEC.  (C)  Cdc42 
staining was weak in the retina, corneal stroma, and LF.  Expression of Cdc42 was 
enhanced in the corneal endothelium and the LEC. 
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Figure 25:  Expression of Rho GTPases in Adult Mouse Eye.   (A)  IHC of the adult 
lens shows RhoA expression is undetectable.  Lens fibers [LF] showed diffuse Rac1 
expression throughout the adult lens.  No detectable Cdc42-specific staining was seen in 
the adult mouse lens.  (B)  RhoA expression in the cornea shows high immunoreactivity in 
the regions of the columnar and squamous cells, as well as elevated in the posterior 
epithelial layer [EpL].    IHC of the adult mouse cornea exhibited elevated expression of 
Rac1 in the columnar and squamous cell regions and moderate staining in the posterior 
endothelium [EnL]; no discernable staining was seen in the corneal stroma.  Cdc42 
expression was primarily isolated to the cornea with a small amount of diffuse staining in 
the posterior endothelium.  (C)  The adult retina showed RhoA staining in every region.  
The staining was strongest in the photoreceptor cell region.  Rac1 was expressed primarily 
in the photosensitive cells, with lesser staining seen outer and inner plexiform layer [IPL] 
as well as in the ganglion cell [GC] layer.  In the retina, elevated expression of Cdc42 was 
found in photoreceptor cells, with less staining in the GC and plexiform cell layers.   
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strong level of expression in the epithelial cells and less in the fiber cells (Fig 25; center 
panel).   The absence of RhoA and Cdc42 in the ocular lens of the adult mouse eye was 
further confirmed by Western blot analysis (Fig. 26).    
Immunohistochemistry revealed that the highest level of RhoA expression in the 
cornea of the adult mouse eye was detected in the endothelial cells and the surface layer of 
epithelial cells (Fig. 25B; leftmost panel) with little detectable staining in the columnar 
cells of the corneal epithelium.  In the corneal stroma, diffuse staining was detected in 
some fibroblasts (Fig. 25B; leftmost panel).  In contrast, Rac1 was predominantly 
expressed in the entire layers of corneal epithelium (both columnar and squamous cell 
layers) but absent in both the corneal stroma and in the endothelial cells layer (Fig. 25B; 
center panel).  For Cdc42, immunocytochemistry demonstrated that it was expressed in 
both the endothelial cell layers and the entire layers of corneal epithelium (both columnar 
and squamous cell layers) but not in the corneal stroma (Fig. 25B; rightmost panel).  To 
further confirm the expression of RhoA, Rac1 and Cdc42 in the cornea of the adult mouse 
eye, western blot analysis was conducted.  As shown in Fig. 26, all three small molecule 
GTPases were detected in the cornea of the adult mouse eye. 
In the retina of the adult mouse eye, immunocytochemistry demonstrated that both 
RhoA and Cdc42 were highly expressed in the photoreceptors, in the 
horizontal/amacrine/Muller cell layers as well as in some of the ganglion cells (Fig. 25C; 
leftmost and rightmost panels).  In most ganglion cells, the inner and outer plexiform 
layers, expression of RhoA and Cdc42 was detectable but in a much reduced level (Fig. 
25C; leftmost and rightmost panels).   For Rac1, a much lower level of expression was
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Figure 26:  Western Blot Analysis of Adult Eye Tissues Corresponds to IHC 
Expression.  Western immunoblot of mouse eye fractions showed significant expression 
of RhoA in the cornea and retina, with no discernable expression in the lens.  Rac1 was 
expressed highly in the lens and retina, as well as moderately in the cornea.  Expression of 
Cdc42 was found to be moderate in the retina and lens using western blot immunoassay.   
 
 96
detected in the retina of the adult mouse eye (Fig. 25C; center panel).  The relative 
expression levels of RhoA, Rac1 and Cdc42 in the adult mouse retina was further 
confirmed by Western blot analysis (Fig. 26). 
Rho Family GTPase Distribution during Ocular Development 
Immunohistochemical analysis of Rho GTPase expression revealed that RhoA, 
Rac1 and Cdc42 are expressed early in mouse ocular development.  Already by day 11.5 
p.c., just as the lens vesicle is formed, expression of the Rho GTPases can be detected in 
the neuroblastic region, as well as throughout the lens cells.  At day 14.5, just after the 
nerve fibers appear and grow towards the optic pit to form the optic stalk, but before they 
are completely differentiated, Rac1 expression becomes significantly elevated in the lens 
and lens fibers.  Expression of Rho members is mostly uniform throughout the retina at 
this stage, with slightly higher expression of Cdc42 in the ganglion cell region.  By day 
17.5 p.c. Rho GTPase expression is concentrated at the outer, actively dividing periphery 
of the lens.  Expression of RhoA, Rac1, and Cdc42 is maintained in neuroblastic regions, 
especially in the inner, nuclear portion of neuroblastic epithelium.   
 In the adult mouse eye, expression patterns of RhoA, Rac1 and Cdc42 continue to 
be distinct to different regions.  RhoA appears to be most highly expressed throughout the 
cornea, particularly in the squamous cells and posterior endothelium with diffused staining 
in the columnar cell layer.  RhoA in the retina is also increased in the photosensitive cells.  
Only slight expression of Cdc42 was seen in either the adult mouse cornea or retina, with 
the highest staining in the columnar cells of the cornea.  Finally, Rac1 was the only 
GTPase detected in the adult lens, however high Rac1 expression was also seen in the 
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cornea within the columnar and squamous cell layers and in the retina with diffuse 
expression in the photosensitive cells, ganglion cells and both inner and outer portions of 
the plexiform layer.   
Rho Family GTPases are Important for Eye Development and Maintenance 
Previous studies have shown that the Rho family of GTPases is essential in 
modulating cytoskeletal rearrangements as well as mediating adhesive and morphological 
properties of the cell, transcriptional regulation and differentiation (Hill et al., 1995; Van 
Aelst and D'Souza-Schorey, 1997).  For that reason, it was not surprising that RhoA, Rac1 
and Cdc42 are all highly expressed during mouse ocular tissue development and continue 
to be specifically expressed in various regions of the adult eye.  Although RhoA is known 
to function in opposition to Rac1 and Cdc42-mediated activity in many cell systems, it is 
likely that the presence of each is essential during eye development.  Our expression 
analysis of the adult mouse showed that each of these Rho GTPases was isolated to 
discrete regions of the adult eye, suggesting that their presence is necessary for the 
maintenance and normal function of these areas.    It is likely that during retinal 
development Rho GTPases play an essential role in regulating neuritogenesis and 
controlling neural cell growth, differentiation, guidance and branching as they have been 
found to regulate similar functions in Xenopus, Drosophila and mammals.  
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Elevated expression of the GTPases, particularly RhoA suggests a crucial role for 
these proteins in modulating eye development.  Additionally, as Rac1 appears to be singly 
expressed at high levels in the adult mouse lens, changes in Rac1 expression and may be 
associated with the development of lens pathologies, such as cataract development and 
age-related structural changes.  Indeed, treatment of cultured lenses with lovastatin shuts 
down Rho signaling-induced cataract formation, suggesting that activity of the Rho 
GTPases is essential in maintaining normal lens morphology (Rao et al., 1997b; Maddala 
et al., 2001b).  In conclusion, our studies that elevated expression pattern of RhoA, Rac1 
and Cdc42 in the developing eye reveals that Rho family of GTPases are potentially very 
important during embryonic development and ocular tissue differentiation.  Differing 
patterns in distribution of each of these proteins in the adult suggests unique roles for the 
Rho family members in normal eye function and maintenance.   
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Discussion 
Immunohistochemical analysis of Rho GTPase expression revealed that RhoA, 
Rac1 and Cdc42 are expressed early in mouse ocular development.  Already by day 11.5 
p.c., just as the lens vesicle is formed, expression of the Rho GTPases can be detected in 
the neuroblastic region, as well as throughout the lens cells.  At day 14.5, just after the 
nerve fibers appear and grow towards the optic pit to form the optic stalk, but before they 
are completely differentiated, Rac1 expression becomes significantly elevated in the lens 
and lens fibers.  Expression of Rho members is mostly uniform throughout the retina at 
this stage, with slightly higher expression of Cdc42 in the ganglion cell region.  By day 
17.5 p.c. Rho GTPase expression is concentrated at the outer, actively dividing periphery 
of the lens.  Expression of RhoA, Rac1, and Cdc42 is maintained in neuroblastic regions, 
especially in the inner, nuclear portion of neuroblastic epithelium.   
In the adult mouse eye, expression patterns of RhoA, Rac1 and Cdc42 continue to 
be distinct to different regions.  RhoA appears to be most highly expressed throughout the 
cornea, particularly in the squamous cells and posterior endothelium with diffused staining 
in the columnar cell layer.  RhoA in the retina is also increased in the photosensitive cells.  
Only slight expression of Cdc42 was seen in either the adult mouse cornea or retina, with 
the highest staining in the columnar cells of the cornea.  Finally, Rac1 was the only 
GTPase detected in the adult lens, however high Rac1 expression was also seen in the 
cornea within the columnar and squamous cell layers and in the retina with diffuse 
expression in the photosensitive cells, ganglion cells and both inner and outer portions of 
the plexiform layer.  
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Previous studies have shown that the Rho family of GTPases is essential in 
modulating cytoskeletal rearrangements as well as mediating adhesive and morphological 
properties of the cell, transcriptional regulation and differentiation (Hill et al., 1995; Van 
Aelst and D'Souza-Schorey, 1997).  For that reason, it was not surprising that RhoA, Rac1 
and Cdc42 are all highly expressed during mouse ocular tissue development and continue 
to be specifically expressed in various regions of the adult eye.  Although RhoA is known 
to function in opposition to Rac1 and Cdc42-mediated activity in many cell systems, it is 
likely that the presence of each is essential during eye development.  Our expression 
analysis of the adult mouse showed that each of these Rho GTPases was isolated to 
discrete regions of the adult eye, suggesting that their presence is necessary for the 
maintenance and normal function of these areas.    It is likely that during retinal 
development Rho GTPases play an essential role in regulating neuritogenesis and 
controlling neural cell growth, differentiation, guidance and branching as they have been 
found to regulate similar functions in Xenopus, Drosophila and mammals.  
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Elevated expression of the GTPases, particularly RhoA suggests a crucial role for 
these proteins in modulating eye development.  Additionally, as Rac1 appears to be singly 
expressed at high levels in the adult mouse lens, changes in Rac1 expression and may be 
associated with the development of lens pathologies, such as cataract development and 
age-related structural changes.  Indeed, treatment of cultured lenses with lovastatin shuts 
down Rho signaling induced cataract formation, suggesting that activity of the Rho 
GTPases is essential in maintaining normal lens morphology (Rao et al., 1997b; Maddala 
et al., 2001a).  In conclusion, our studies that elevated expression pattern of RhoA, Rac1 
and Cdc42 in the developing eye reveals that Rho family of GTPases are potentially very 
important during embryonic development and ocular tissue differentiation.  Differing 
patterns in distribution of each of these proteins in the adult suggests unique roles for the 
Rho family members in normal eye function and maintenance.   
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CHAPTER VII 
RHO FAMILY GTPASE REGULATION OF LENS EPITHELIAL DIFFERENTIATION 
 
Overview 
Development and differentiation of lens tissue require precise regulation of cellular 
pathways regulating the unique structural organization which affords the lens its 
transparency and ability to focus light.  Although structurally simple and composed of a 
single metabolically active layer of epithelial cells, any anomaly in normal function and 
maintenance can lead to a multitude of pathologies including cataractogenesis, presbyopia 
and blindness.  Western blot analysis in conjunction with immunohistochemistry has 
indicated a possible correlation between heightened Rac1 expression and increased levels 
of lens differentiation.  In vitro data using lens epithelial cell culture has identified a direct 
relation between active levels of Rac1 and higher expression of the lens cell differentiation 
marker, β-crystallin.  Luciferase assays indicate modulation of crystallin promoter 
activation upon activation of Rac1 using GEFT, a guanine nucleotide exchange factor 
expressed in the lens.  Additionally, analysis of the promoter region of αB-crystallin has 
revealed the presence of multiple putative SRF sites, a direct downstream effector of 
activated Rac1.  Here we show that SRF modulates lens cell differentiation through its 
regulation of crystallin transactivation via activation of Rac1 small molecule GTPase. 
Introduction 
Nearly one in every six Americans over the age of 40 is affected by cataracts, a 
statistic that involves over 20 million in the United States alone; worldwide, the number 
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would staggering.  Thus great efforts are being made to understand the development and 
maintenance of the normal lens in order to better treat lenticular defects and opacification.  
The lens consists of a single actively dividing epithelial layer.  As new lens epithelial cells 
form, older cells will migrate posteriorly, become elongate and gradually differentiate into 
lens fibers.  These lens fibers, although anuclear and quiescent in nature, are structurally 
highly differentiated.  Lens differentiation is initiated and controlled by numerous growth 
factors, including TGF-β, fibroblast growth factor (FGF) and bone morphogenetic proteins 
which are found in the vitreous humor (Zelenka, 2004).  These growth factors then 
modulate cytoskeletal alterations that transform the cuboidal lens epithelial cell shape into 
the elongate-shape characteristic of the lens fiber.  Additionally. the migration of 
differentiating epithelial cells away from the metabolically active region requires 
coordination of cell-cell and cell-matrix interactions.  Such cytoskeletal alterations, cell 
migration and adhesion necessary for normal lens differentiation are all functions regulated 
by the Rho family of small molecule GTPases (Zelenka, 2004).  Consequently, there has 
recently been a growing interest in determining the function of the Rho family in lens 
development and differentiation, as well as in the possible role the Rho family has in 
modulating lens pathologies, particularly opacification leading to cataractogenesis. 
Genes encoding membrane and cytoskeletal proteins, as well as the lens crystallins 
have all been found to contribute to the formation of cataracts.  Lens crystallin proteins 
consist of three major classes, α, β and γ, all having different functions within the lens.  
Alpha-crystallins are particularly important as they are the proteins which maintain lens 
transparency.  Alpha crystallins act as molecular chaperones and aberrations in their 
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function and in their expression lead to abnormal protein aggregation that can cause to 
opacification (Zelenka, 2004).  The following research demonstrates that the crystallin 
promoter activation is under the control of the Rho family of small molecule GTPases, 
specifically Rac1.  Immunohistochemistry and western blot analysis show that the highest 
levels of Rac1 expression are reached during periods of high lens epithelial cell 
differentiation and this consequently leads in Rac1 mediated activation and nuclear 
localization of SRF which transactivates crystallin expression. 
Differential Expression of Rac1 in the Lens  
Historically, the Rho family of small molecule GTPases are considered to be 
uniformly expressed throughout tissues.  New studies, however, suggest that unique 
temporal and spatial expression of the Rho family in areas such as the brain are essential 
for normal development and cellular differentiation.  Initially, our lab sought to determine 
whether there was differential expression of the major Rho family members: RhoA, Rac1 
and Cdc42 within the various tissues of the eye.  Western blot analysis of corneal, 
lenticular and retinal tissues revealed that unlike RhoA and Cdc42, Rac1 was highly 
expressed in the adult mouse lens tissue (Figure 27A).  Additionally, immunoblot of lens 
tissues from young, adult and aged mice showed increased Rac1 expression in the highly 
differentiating young mouse lenses (∼2 weeks) and in the aged mouse lenses (>1 year) 
(Figure 27B).  These results suggest that unique Rac1 expression in the eye is both spatial 
(expressed highly in the lens) and temporal (expressed at different times of development).
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Figure 27:  Unique Spatial and Temporal Expression of Rac1 in the Lens. 
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In addition, Rac1 was found to be expressed during periods of heightened lenticular 
differentiation:  early, when lens cell differentiation is high, and in older mice when such 
differentiation might indicate aberrant cellular function and the development of lens 
pathologies.  
Process of Lens Dell Differentiation Leads to Heightened Levels of Activated Rac1  
To understand the potential role of Rac1 is lens differentiation, we used N/N003A 
rabbit lens epithelial cell line.  As N/N003A cells become confluent, they become more 
differentiated and take on more characteristics of lens fibers, including more elongate 
shape and increased expression of β-crystallin, a marker of lens differentiation.  Levels of 
activation were measured at three timepoints: 70% confluency, 100% confluency and 
100% confluency after three days.  Using activated-GTPase pull-down assays, we found 
that while total Rac1 levels increase only slightly (Figure 28), activated levels of the 
protein increase more dramatically.  Conversely, RhoA activation decreased upon 
increased confluency and Cdc42 saw a slight increase both in total levels and in activated 
levels of the protein. 
Activator of Rho family GTPases is Expressed Throughout the Eye 
In order to determine whether activation of Rac1 was essential for Rac1 mediated 
lens differentiation, we used a guanine nucleotide exchange factor, GEFT, that regulates 
activation of the Rho family members, including Rac1, by inducing Rac1 dissociation from 
its inactive GDP-bound form to its active GTP-bound form (Figure 29A).  To show that 
GEFT activation was physiologically relevant to Rac1 activation in the lens, we initially 
carried out western blot analysis of different fractions of the eye using a GEFT-specific
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Figure 28:  Differential Expression of Activated Rac1 in Lens Cell Culture.  
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Figure 29:  Rac1 Activator, GEFT, Expressed in the Lens. 
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antibody (Figure 29B).  Results showed that GEFT was ubiquitously found throughout the 
different regions of the eye, including the lens fibers and lens epithelium.  These results 
suggested that using GEFT-AAV infection of N/N003A cells would be a credible means of 
testing effects of Rac1 activation in lens culture. 
GEFT Infection Increases Active Levels of Rho Family GTPases  
N/N003A cells were infected with an AAV virus carrying a human isoform of 
GEFT.  Activated-GTPase pull-downs using GST-tagged Pak and Rhotekin beads, was 
then used to determine activation of Rac1, Cdc42 and RhoA in cell culture.  Results 
showed that whereas total levels of Rho family proteins was unaltered, the active form of 
all three Rho GTPases was significantly enhanced in the GEFT-infected cells (G) as 
compared to the vector-only transfected lens cells (V) (Figure 30).  This data supports that 
while GEFT does not affect total levels of Rho family of protein, it does induce activation 
of all three major members in lens cell culture. 
Lens Fiber Differentiation Ablated by Rac1 Specific Inhibitor 
Inhibition of Rac1 in cell culture was mediated through use of the Rac1 specific 
chemical inhibitor,  NSC23766.  This inhibitor functions by interfering with Rac1 
interaction with two major GEF proteins, Trio and Tiam1.  To determine whether this 
Rac1 inhibitor would interrupt GEFT-Rac1 interaction, immunoblot and lens cell 
confluency analysis was used to determine degree of lens differentiation upon treatment.  
N/1003A cells were grown at 70% confluency and 100% confluency for 3 days; cells were 
untreated, GEFT-AAV infected, treated with 50 µM Rac1 inhibitor, or infected with 
GEFT-AAV and treated with Rac1 inhibitor (Figure 31).  Results show that GEFT-AAV
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Figure 30:  GEFT Infection Increases Active Rho GTPases 
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Figure 31:  Lens Differentiation Ablated by Rac1 Inhibitor 
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infection induces high levels of cellular elongation characteristic of lens differentiation into 
lens fibers as compared to untreated.  In addition, cells which were treated with the Rac1 
inhibitor showed no significant morphological differences as compared to the untreated.  
However, treatment of GEFT-AAV infected cells with the Rac1 inhibitor ablated elongate 
cell morphology changes.  Additionally, western blot analysis revealed that whereas GEFT 
infection induced high expression of the lens differentiation marker, β-crystallin, this effect 
was abolished upon treatment with Rac1 inhibitor (Figure 32).  These results support Rac1 
activation as a key mediator of lenticular differentiation. 
Rho Family GTPase Regulation of Crystallin Expression 
Crystallin expression is a marker for lens cell differentiation.  As such, our lab 
attained luciferase constructs containing the promoter regions for six different crystallin 
proteins (two α-, two β- and two γ- crystallins).  These constructs were transfected into 
N/N1003A cells along with RhoA, Rac1 and Cdc42, GEFT and the dominant negative 
forms of the Rho family members (Figure 33).  Results showed that activation of the 
crystallin promoter (representative luciferase shown here) was attained only upon co-
transfection of Rac1 with GEFT and this transactivation was ablated upon overexpression 
of the dominant negative form of Rac1, Rac1 T17N.  Additionally, treatment of crystallin 
promoter-transfected N/N1003A cells using inhibitors to major signaling pathways, 
including inhibitors of JNK, Gαq, Rho kinase, p38, RhoA and the Rho GTPases revealed 
that inhibition of the Rho family using Toxin A led to inhibition of basal crystallin 
expression.  These results showed that while Toxin A ablated basal crystallin 
transactivation, inhibition  
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Figure 32:  Rac1 Inhibitor Prevents β-Crystallin Expression. 
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Figure 33:   GEFT-Activated Rac1 Regulation of Crystallin Expression. 
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Figure 34:  Rho GTPase Inhibitor, Toxin A, Obliterates Crystallin Transactivation. 
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of RhoA using Lovastatin did not inhibit crystallin promoter activation, suggesting a 
GTPase other than RhoA was responsible for the effect (Figure 34). 
SRF Responsible for Mediating Lenticular Differentiation via Rac1 Activation 
To determine the underlying signaling pathways modulated by activated Rac1 
leading to lens differentiation, western blot analysis on the major downstream effectors 
was done using lysates from lens cells (Figure 35).  The MAPK signaling pathways is the 
major signaling intermediary of Rac1 effects, however, our data showed no 
phosphorylation of ERK, p38 or JNK or significant changes in expression of total protein 
levels (Figure 35).  Another major mediator of Rac1 effects is the serum response factor 
(SRF).  To determine if SRF played a role in modulating lens differentiation via Rac1 
activation, SRF was co-transfected along with Rac1 and GEFT in N/N1003A cells 
expressing αB-crystallin promoter (Figure 36).  Although SRF increased GEFT and Rac1 
mediated induction of αB-crystallin promoter activation, a SRF mutant lacking the c-
terminal nuclear localization sequence, SRF∆ diminished αB-crystallin transactivation to 
basal levels.  These results indicate the necessity of SRF action in the nucleus, likely as a 
transcription factor. 
Activation of Rac1 in Lens Epithelial Cells Induces SRF Nuclear Localization 
Considering the importance of the SRF nuclear localization sequence in inducing 
αB-crystallin transcriptional activation, immunofluorescence of GEFT infected cells was 
used to determine if Rac1 activation by GEFT induced nuclear localization of SRF (Figure 
37).  N/N1003A cells on glass coverslips were transfected with GEFT-flag and SRF-HA or 
Vector with SRF-HA, fixed and incubated with the appropriate antibodies.  Results  
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Figure 35:  Lens Differentiation Not Dependent on MAPK Pathway. 
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Figure 36:  SRF Mediates Lens Differentiation via Rac1 Activation. 
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Figure 37:  Rac1 Activation Induces SRF Nuclear Localization. 
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showed that SRF-HA was localized to the Hoechst-stained nuclei in the GEFT+Rac1 
transfected cells, whereas no such nuclear localization was seen in vector-only transfected 
cells, suggesting activation of Rac1 may induce translocation of SRF to the nucleus. 
Discussion 
Serum response factor (SRF) is a mammalian transcription factor which is capable 
of acting as either a homodimer or by binding numerous other proteins to modulate 
transcription  SRF most notably controls regulation of immediate early genes such as egr-1 
and c-fos, as well as genes involved in myogenesis and is not surprisingly largely 
controlled through Rho mediated pathways (Carnac et al., 1998; Montaner et al., 1999; 
Psichari et al., 2002; Schratt et al., 2002).  Aberrant SRF-mediated transactivation has 
previously been associated with pathologies of the vascular smooth muscle as well as 
smooth muscles of the respiratory system (Affolter et al., 1994; Guillemin et al., 1996; Lu 
et al., 1998; Ding et al., 2001).  In addition, SRF is highly expressed throughout early 
developmental stages in the region of the eye, and its targeted disruption is lethal during 
the embryonic stages of mouse development suggesting it is a likely mediator of early lens 
differentiation (Arsenian et al., 1998; Weinhold et al., 2000; Wiebel et al., 2002)    
 Thus far, our results indicate a possible molecular mechanism underlying lenticular 
differentiation by which activated Rac1 in the lens induces SRF nuclear localization which 
induces transcriptional activation of the crystallin genes.  We are currently determining 
whether putative SRF responsive elements (SREs) within the αB-crystallin promoter, and 
the promoters of numerous other crystallins directly mediates transcriptional regulation.  
Additionally, lens explant culture of whole lens epithelial layers harvested and cultured in 
 
 121
Rac1 inhibitor is resistant to TGF-β-induced lens differentiation and opacification.  If these 
results are positive, this study will show a novel mechanism regulating lens differentiation 
and crystallin control via activated Rac1 effect on SRF localization.   
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 CHAPTER VIII 
SUMMARY AND CONCLUSIONS 
 
The majority of my Ph.D. research focused on understanding different aspects of 
the human metastasis suppressor peptide, KiSS-1:  the transcriptional mechanisms by 
which it is regulated, identification of signaling intermediaries downstream of its cognate 
G-protein coupled receptor, and the means by which it becomes lost during metastatic 
progression.  As the anti-metastatic effects of KiSS-1 register through activation of its 
membrane receptor, I began by developing a yeast-two-hybrid system in which the 
intercellular region of the receptor, including a SH3 binding domain, was used as bait to 
look for direct protein interaction.  This analysis yielded multiple candidate proteins which 
were subsequently tested and verified using GST-pulldowns and cell culture-based co-
immunoprecipitation assays.  Results indicated direct binding of the KiSS-1 receptor with 
at least two SH3 domain-containing proteins, PSGAP (PH and SH3 domain containing 
Rho GTPase activating protein) and the guanine nucleotide exchange factor, Vav1.  These 
findings are significant as they provide a mechanism whereby KiSS-1 regulates control of 
the Rho family of small molecule GTPases, a family of proteins known to regulate 
cytoskeletal re-organization, and may thus explain the basis of KiSS-1’s anti-metastatic 
effects as it alters signaling to the actin-based cytoskeleton to reduce migration and 
invasion.  Additionally, my research helped support the role of the MAPK pathway in 
registering the intercellular effects of KiSS-1.  Treatment of metastatic breast cancer cells 
with synthetic KiSS-1 peptide heightened adhesive properties of the cell and induced 
 
 123
changes in phosphorylated levels of P38, ERK and JNK.  Addition of chemical inhibitors 
which block these different pathways resulted in loss of pathway activation and aberrant 
cellular activity and morphology, suggesting that each plays a major role in mediating the 
effects of KiSS-1. 
During my Ph.D. research, I also determined two distinct and cell-type specific 
means whereby KiSS-1, like many metastasis suppressor genes, is lost during metastatic 
progression.  Previous studies had indicated a correlation between reduced KiSS-1 
expression and a loss of certain chromosomal regions.  I identified that loss of two 
proteins, a transcription factor and a transcription co-factor, encoded by these regions 
caused the ensuing loss of KiSS-1 transcription in metastatic cells.  Initially I identified 
two distinct AP-2α binding elements on the KiSS-1 promoter which mediated KiSS-1 
transcriptional control and demonstrated that loss of AP-2α or targeted mutation of the two 
binding elements significantly reduced KiSS-1 levels in vitro.  This was the first data to 
provide a mechanism for the loss of KiSS-1 during metastatic progression of breast cancer.  
Additionally, as KiSS-1 correlates directly to the degree of metastatic severity in human 
patients and its expression is dependent upon transactivation by AP-2α, this research also 
supported the use of AP-2α as a potential biomarker for identifying strong metastatic 
potential of certain breast cancers.  A second, similar study looked at the effects of the 
transcriptional co-factor DRIP-130 on activation of the KiSS-1 promoter.  A subunit of 
CRSP, DRIP-130 targets the common transcription factor, Sp1 to a promoter.  My research 
indicated that activation of the KiSS-1 promoter, which contained multiple Sp1 sites, 
required DRIP-130 expression and that chromosomal loss of the region encoding DRIP-
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130 resulted in abrogated transactivation of the promoter in highly metastatic melanoma.  
Using both EMSA and CHIP analysis as before in the AP-2α study, I was able to isolate 
the DRIP-130-modulated region of the KiSS-1 promoter and indicate a potential 
mechanism by which KiSS-1 is lost during progression of melanoma. 
The last of my Ph.D. research focused on the spatial and temporal expression of the 
Rho family of GTPases in the mouse lens and their differential activation during lenticular 
differentiation.  As the Rho family proteins are closely associated with cytoskeletal 
changes and cellular differentiation, I looked at possible roles of Rho regulation in normal 
and abnormal lens cell differentiation.  Western analysis and immunohistochemistry 
suggested that activation of Rac1, a Rho protein associated with lamellapodia formation, 
correlated to periods of heightened lens differentiation.  In order to examine the effects of 
Rac1 activation in vitro, I then developed a cell culture-based system in which I found that 
I could differentiate N/N1003A rabbit lens epithelial cells using a promiscuous guanine 
exchange protein which activated Rac1.  In addition, I found that inhibition of Rac1 
activation with a specific chemical inhibitor in both my cell culture system and lens 
explants resulted in loss of differentiation as gauged by decreased levels of β-crystallin and 
profilin, markers of lens differentiation.  Immunofluorescence further revealed that 
activated Rac1 induced SRF nuclear localization, a transcription factor, which upregulates 
the expression of a β-crystallin promoter-driven luciferase construct and induces lens 
differentiation. 
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The results of this dissertation research have made significant strides in 
understanding the nature of the anti-metastatic effects registered by the novel KiSS-1 
peptide and its cognate GPCR.  Additionally, it has shed light on the Rho family regulation 
of lens epithelial cell differentiation, indicating the elaborate involvement of Rac1 in 
mediating lens fiber development.  In all, this research has determined previously unknown 
roles of small molecule GTPases in both the progression of metastasis, as well as in normal 
and abnormal lens cell differentiation. 
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NOMENCLATURE 
 
AAV  Adeno-Associated Virus 
AP-2α  Activator Protein-2alpha 
CDK  Cyclin Dependent Kinase 
ChIP  Chromatin Immunoprecipitation 
DRIP-130 Vitamin D Receptor Interacting Protein-130 
ECM  Extracellular Matrix 
EGF  Epidermal Growth Factor 
EMSA  Electrophoretic Mobility Shift Assay 
EtBr  Ethidium Bromide 
FAK   Focal Adhesion Kinase  
FGF  Fibroblast Growth Factor 
GDP  Guanine Di-Phosphate 
GEF  Guanine Nucleotide Exchange Factor 
GPCR  G-Protein Coupled Receptor 
GST  Glutathione S-Transferase 
GTP  Guanine Tri-Phosphate 
JNK  Jun N-Terminal Kinase 
LPA  Lysophosphatidic Acid  
MAPK  Mitogen Activated Protein Kinase 
MLC  Myosin Light Chain 
MMP  Matrix Metalloproteinase 
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NF-κB  Nuclear Factor-kappaB 
PAK  P-21 Activated Kinase 
PCO  Posterior Capsular Opacification 
PDGF  Platelet Derived Growth Factor 
PLC-β  Phospholipase C-β 
RT-PCR Reverse Transcriptase-Polymerase Chain Reaction 
SP1  Specificity Protein 1 
SRE  Serum Response Element 
SRF  Serum Response Factor 
TGF  Transforming Growth Factor 
TGF-β  Transforming Growth Factor-β 
VEGF  Vascular Endothelial Growth Factor 
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